



Invited review

Peptides and peptide-derived molecules targeting the intracellular domains of Cx43: Gap junctions *versus* hemichannels



Jegan Iyyathurai^{a,1}, Catheleyne D'hondt^{a,1}, Nan Wang^b, Marijke De Bock^b, Bernard Himpens^a, Mauricio A. Retamal^c, Jimmy Stehberg^{d,e}, Luc Leybaert^b, Geert Bultynck^{a,*}

^a KU Leuven, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, Campus Gasthuisberg O/N-I Bus 802, Herestraat 49, BE-3000 Leuven, Belgium

^b Faculty of Medicine and Health Sciences, Physiology Group, Department of Basic Medical Sciences, Ghent University, De Pintelaan 185 (Block B-Rm 310), B-9000 Ghent, Belgium

^c Departamento de Fisiología, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile

^d Universidad Andres Bello, Laboratorio de Neurobiología, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas & Facultad de Medicina, Santiago, Chile

^e Universidad Andres Bello, Centro de Investigaciones Biomédicas, Santiago, Chile

ARTICLE INFO

Article history:

Received 2 January 2013

Received in revised form

17 April 2013

Accepted 18 April 2013

Keywords:

Connexin

Gap junctions

Hemichannels

Intramolecular interactions

Cytoplasmic loop

C-terminal tail

Peptides

Ischemia

Brain

Heart

ABSTRACT

About a decade ago, the molecular determinants controlling the opening and closing of Cx43 gap junction channels have been identified. Advanced biophysical approaches revealed a critical role for structural rearrangements in the cytoplasmic loop and dimerization of the C-terminal tail, resulting in binding of the C-terminal tail to the cytoplasmic loop and Cx43 gap junction channel closure during cellular acidosis. This has spurred the development of Cx43-mimetic peptides and peptidomimetics that interfere with these loop/tail interactions, thereby preventing the closure of Cx43 gap junctions, *e.g.* in the heart upon ischemia. Recently, we found that loop/tail interactions control Cx43-hemichannel activity but with an opposite effect. Binding of the C-terminal tail to the cytoplasmic loop is a requisite for the opening of Cx43 hemichannels in response to different stimuli, like decreased extracellular $[Ca^{2+}]_i$, increased intracellular $[Ca^{2+}]_i$, positive membrane potentials or ischemia. Strikingly, peptides that favor the open state of Cx43 gap junctions like the L2 peptide inhibit Cx43-hemichannel opening. These tools now provide unprecedented opportunities to selectively inhibit Cx43 hemichannels while maintaining Cx43 gap junction communication, impossible to achieve with siRNA or knockdown approaches both affecting gap junctions and hemichannels. These tools not only are very helpful to unravel the role of Cx43 hemichannels in complex biological systems, but also hold therapeutic potential to counteract excessive Cx43-hemichannel activity like in ischemia/reperfusion in the brain and the heart or to prevent Cx43 hemichannel-mediated gliotransmitter release in the basal amygdala during memory consolidation in response to emotional events.

This article is part of the Special Issue Section entitled 'Current Pharmacology of Gap Junction Channels and Hemichannels'.

© 2013 Published by Elsevier Ltd.

1. Introduction

Intercellular communication is critical for regulating a plethora of physiological processes in many organs and tissues critical for life, including the brain, heart, kidney, liver, pancreas, lung, arteries, ovary, bone, inner ear, skin, lens, retina and cornea as most

important ones (Kar et al., 2012; Leybaert and Sanderson, 2012; Saez et al., 2003). For instance, the synchronization of the contraction of cardiomyocytes, the coordination of metabolic networks in the brain and the generation of rhythmic contractions in the arteries critically depend on the proteins that establish intercellular communication, the connexins (Cx) and pannexins (Panx)-protein family (Billaud et al., 2012; Delmar and Makita, 2012). These proteins are ubiquitously expressed in human tissues and are encoded by 21 genes for Cxs and 3 genes for Panxs (D'hondt et al., 2009; Scemes et al., 2009, 2007). These proteins

* Corresponding author. Tel.: +32 16 330215.

E-mail address: geert.bultynck@med.kuleuven.be (G. Bultynck).

¹ These authors equally contributed to this work.

assemble in hexameric channel complexes (though Panx2 might form an octamer (Ambrosi et al., 2010)), which can either function as head-to-head-docked gap junction channels establishing direct cell-to-cell contacts or free unapposed hemichannels establishing release nodes for signaling molecules affecting neighboring cells (D'hondt et al., 2009; Herve and Derangeon, 2013; Scemes et al., 2009). It is well established that Cx isoforms can function both as gap junction channels and hemichannels (Evans et al., 2006; Kar et al., 2012). For Panx isoforms, recent evidence from over-expression studies suggests that they may also function as gap junction channels (Ishikawa et al., 2011) although still under debate (Sosinsky et al., 2011). Moreover, Cx and Panx channels may also appear at intracellular membranes, including the mitochondria and the endoplasmic reticulum (ER), where they may function as nonjunctional channels. Cx43 found at the inner mitochondrial membrane has been implicated in K^+ flux into the mitochondria of cardiomyocytes (Miro-Casas et al., 2009), whereas ER-localized Panx channels may function as intracellular Ca^{2+} -leak/release channels (D'hondt et al., 2011; Ishikawa et al., 2011; Vanden Abeele et al., 2006). Very recently, a new protein family, Ca^{2+} -homeostasis modulator 1 (CALHM1), has been identified and reported to resemble structurally and functionally Cx/Panx channels (Siebert et al., 2013). CALHM1 seems to function as a non-junctional channel responsible for ATP release, especially in the taste bud cells, involved in the sensation of bitter, sweet and umami tastes (Taruno et al., 2013).

In this review, we will focus on the 43-kDa Cx isoform (Cx43), which is highly and widely expressed, in particular in the heart and the brain (Kar et al., 2012; Scemes et al., 2009). The biological role of Cxs, including Cx43, as gap junction and nonjunctional channels has recently and extensively been discussed in other reviews (Chandrasekhar and Bera, 2012; Kar et al., 2012; Wang et al., 2013a). In short, as reported in many cell types and tissues, Cx-based gap junctions provide ionic/electrical conductance (Na^+ , K^+ , Ca^{2+}), metabolic coupling (ATP/ADP, glucose, glutamate, glutathione) and spreading of secondary messenger molecules (IP_3 , cAMP) between cells (Kar et al., 2012). Also, Cx-based hemichannels mediate the flux of many substances, including ions and molecules with a molecular weight (MW) lower than 1–2 kDa, including ATP, NAD^+ , glutamate, glutathione, prostaglandin E_2 and epoxyeicosatrienoic acids (D'hondt et al., 2009; Wang et al., 2013a). These molecules provide local/paracrine signaling networks implicated in the control and coordination of intracellular and intercellular signaling pathways involved in cell survival, proliferation and death (Decrock et al., 2013, 2009b; Leybaert and Sanderson, 2012). The physiological role of Cx hemichannels has been questioned (Scemes, 2012), although it is increasingly clear that diverse stimuli within physiological conditions can modulate the opening of Cx hemichannels, including low extracellular $[Ca^{2+}]_o$ as occurs during neuronal synaptic signaling (Torres et al., 2012), moderate elevation of intracellular $[Ca^{2+}]_i$ in the physiological range of ~ 500 nM (De Vuyst et al., 2006; De Vuyst et al., 2009; Wang et al., 2012, 2013a) and mechanical forces/shear stress (Loiselle et al., 2013). Furthermore, physiological elevations of intracellular $[Ca^{2+}]_i$ shifted the threshold for voltage-dependent opening of Cx43 hemichannels from +60 mV to +40 mV and lower (Wang et al., 2012). This indicates that physiological Ca^{2+} signaling may sensitize the opening of Cx43 hemichannels in response to membrane polarization to potentials in the +30 mV to +40 mV range which may occur in electrically excitable cells. On the other hand, the excessive opening of Cx hemichannels can be limited physiologically by the actomyosin cytoskeleton involving Ca^{2+} and RhoA signaling, thus avoiding detrimental effects on cellular homeostasis (Ponsaerts et al., 2008, 2012a,b). Finally, post-translation modifications can also influence and regulate the activity of Cx43 hemichannels (Johnstone et al., 2012).

The monomeric Cx43-building blocks that form hexameric channels consist of a 382 amino acid-long protein (based on the human Cx43 sequence; NCBI Reference Sequence: NP_000156.1) containing four-transmembrane domains with two extracellular loops, one cytoplasmic loop domain and an N- and C-terminus that faces the cytoplasmic side. The N-terminus is relatively short (13 amino acids), while the C-terminus is relatively long (~ 150 amino acids). The C-terminus is very important for the regulation of Cx43-gap junction channels, containing a number of phosphorylation sites, protein-interaction sites and motifs as well as redox-sensitive residues (three Cys residues) (Herve et al., 2007; Johnstone et al., 2012; Palatinus et al., 2012; Solan and Lampe, 2009). In this review, we will focus on the role of loop/tail interactions for controlling the activity of Cx43 gap junction channels and hemichannels. We will also discuss how recent insights on the key determinants underlying loop/tail interactions and their functional outcome for Cx43 gap junction channels and hemichannels has spurred the development of novel peptides and peptidomimetics with therapeutic potential. In particular, recent advances resulted in the identification of peptides that can sustain gap junction coupling in disease conditions and peptides that can prevent excessive hemichannel opening under certain pathological conditions (Evans et al., 2012). These peptides are promising tools to explore the role of gap junctions and Cx hemichannels in pathological conditions and diseases, and offer interesting possibilities towards defining novel molecular therapeutic targets (De Vuyst et al., 2011; Evans et al., 2012; Herve and Dhein, 2010).

2. Intramolecular loop/tail interactions in Cx43 gap junction channels and their functional consequences

2.1. Gap junction channels paved the path

About twenty years ago, the role of intramolecular interactions in the gating of Cx43 gap junction channels started to emerge (Liu et al., 1993) (Fig. 1). The original findings were directed towards providing a mechanistic basis for the intracellular acidification-mediated closure of Cx43 gap junction channels (Spray et al., 1981), but were also found to be applicable to other forms of chemical gating, for example gap junction closure induced by insulin (Homma et al., 1998). Liu et al. found that Cx43-based gap junction channels were particularly sensitive to a decrease in intracellular pH (pH_i) compared to Cx32 or CT-truncated Cx43 (Cx43^{M257})-based gap junction channels (Liu et al., 1993). The junction conductance rapidly decreased starting from pH_i 6.8 and lower for Cx43, while for Cx32 and Cx43^{M257}, junction conductance only started to decrease from pH 6.3 and below (Fig. 2). Hence, the C-terminal tail of Cx43 seemed critical for the pH-dependent gating of the Cx43 gap junction channels (Fig. 1). Further work revealed critical elements in the cytoplasmic loop and its preceding transmembrane domain (transmembrane domain 2, see Fig. 3), revealing a critical role for His95 (Ek et al., 1994). Replacing His95 to Asp or Tyr led to functional Cx43 gap junctions that displayed a decreased susceptibility towards intracellular acidification. In contrast, replacing His95 to Lys led to functional Cx43 gap junctions that displayed an increased susceptibility towards intracellular acidification. Thus, His95 is critical for the pH-dependent regulation of Cx43 gating, likely via a protonation mechanism that would lead to a positively charged residue, strengthening the interaction with the negatively charged CT. Follow-up studies showed that the lack of sensitivity of Cx43^{M257} gap junction channels to intracellular acidification (in the range between pH 7.2 to pH 6.4) was restored upon co-expression of the C-terminal tail (amino acids 259–382) (Morley et al., 1996). Hence, the C-terminal tail of Cx43 acts as a




Fig. 1. Schematic representation of Cx43 gap junctions and hemichannels in the open and closed state. The Cx43 protein is the building block for gap junctions and hemichannels, consisting of a short N-terminus, 4 transmembrane domains, two extracellular loops, one cytoplasmic loop and a long C-terminal tail. Functional channels consist of hexameric structures that are head-to-head docked to form gap junctions or that are unopposed to form hemichannels. Gap junctions: At normal conditions ($\text{pH} > 7.0$), gap junctions are open (green) and the C-terminal tail does not interact with the cytoplasmic loop. During ischemia (or other conditions that cause a drop in pH), the C-terminal tail dimerizes and the cytoplasmic loop restructures adopting two α -helical structures at the proximal and distal part of the L2 region, resulting in the binding of the C-terminal tail to the cytoplasmic loop and the closure of gap junction channels (red). Peptides like L2 (but also others) interfere with these loop/tail interactions by replacing the endogenous cytoplasmic loop of Cx43 and serving as a binding partner for the C-terminal tail, maintaining the open state of gap junction channels (green). Hemichannels: At normal conditions ($\text{pH} \sim 7.0$), hemichannels are closed (red) due to the lack of the binding of C-terminal tail to the cytoplasmic loop. During ischemia, but also other conditions that open hemichannels like a decrease in extracellular $[\text{Ca}^{2+}]$ or increase in intracellular $[\text{Ca}^{2+}]$ (up to 500 nM), hemichannels are opened (green) due to the binding of the C-terminal tail to the cytoplasmic loop. Peptides like L2 and Gap19 interfere with the loop/tail interactions by binding to the C-terminal tail and preventing endogenous loop/tail interactions that are critical for hemichannel opening. For clarity reasons, the monomeric building blocks are depicted, but it should be noted that the functional hemichannel unit is hexameric.




Fig. 2. Function of C-terminally truncated Cx43 gap junctions and hemichannels. Gap junctions: C-terminally truncated Cx43 gap junctions remain open, but are resistant to low pH_i -induced closure. Hemichannels: C-terminally truncated Cx43 hemichannels remain closed, even at low pH_i or other stimuli, like decreased extracellular $[\text{Ca}^{2+}]$ or increased intracellular $[\text{Ca}^{2+}]$. As in Fig. 1, only monomeric building blocks are shown for clarity.

separate and independent domain that binds to a region preceding the C-terminal tail and closes Cx43-gap junction channels upon intracellular acidification. Elements in the first 257 amino acids were proposed to act as a receptor for elements in the last 124 amino acids, acting as a particle (Morley et al., 1996). Two regions within the C-terminal tail of Cx43 were found to be particularly critical for intracellular acidification-induced uncoupling, one region covers amino acids 261–300 and another region covers amino acids 374–382 (Ek-Vitorin et al., 1996). Deleting these two regions in Cx43 renders these gap junction channels relatively insensitive to intracellular acidification-induced uncoupling. Region 261–300 contains a proline-rich region, identified as the SH3-binding domain of Src, a protein tyrosine kinase (Kanemitsu et al., 1997; Sorgen et al., 2004a). Pro277 and Pro280 seem to play a critical role in the structural integrity of this region. Mutating these Pro residues into Ala results in Cx43 gap junction channels resistant to intracellular acidification, which mimics the behavior of Cx43^{Δ261–300} gap junction channels. Region 374–382, which corresponds to the PDZ2-binding site for Zonula Occludens-1 (ZO-1) (Giepmans and Moolenaar, 1998; Sorgen et al., 2004a), also contains two Pro residues (Pro375 and Pro377) and a set of positively charged residues (Arg374 and Arg376) and negatively charged residues (Asp378, Asp379 and Glu381). The three negative charges seemed critical for the pH_i gating of the Cx43 gap junction channels, as the simultaneous mutation of these residues abolished the pH_i -induced closure of these channels. Thus, interactions of the particle with its receptor domain seem to depend on ionic and non-ionic interactions. These concepts may not necessarily be limited to domain interactions within Cx43, but may also be applicable for some other Cx isoforms, like Cx40 (Gu et al., 2000; Stergiopoulos et al., 1999). Certainly, not all Cx isoforms display this regulation. For example, C-terminal truncation of Cx45 did not affect its pH_i -dependent regulation (Stergiopoulos et al., 1999). Furthermore, also hetero-domain interactions may occur, as shown between Cx43 and Cx40. The pH_i -dependent regulation of C-terminally truncated Cx43 could be restored by the C-terminal tail of Cx40 and *vice versa*, while the C-terminal tail of Cx43 could render Cx26 and Cx32, which normally are resistant to chemically-induced closure, sensitive to insulin (Stergiopoulos et al., 1999). All these functional studies hinted towards a critical role for the C-terminal tail of Cx43 in pH_i -dependent regulation of Cx43 gap junction channels through intramolecular interactions (Fig. 1). A detailed molecular analysis using different biophysical approaches led to the identification of the second part of the cytoplasmic loop (the L2 region corresponding to amino acids 119–144 of Cx43) as the receptor for the C-terminal tail particle (Duffy et al., 2002) (Fig. 3). The authors showed a pH-dependent interaction between the L2 region and the C-terminal tail of Cx43 (Fig. 1). A strong interaction between L2 and the C-terminal tail of Cx43 was observed at pH 6.5, while binding was not observed at pH 7.4. Importantly, the L2 region contains two His residues (His126 and His144), which are protonated at low pH and are likely involved in structural rearrangements of the L2 region (Fig. 3). These two His residues are located in two separate regions that were shown to form α helices in the solution structure of the L2 region obtained at pH 5.8. The critical role of these His residues in the gating of Cx43 gap junction channels was further underpinned by the analysis of Cx43^{H144E} gap junction channels (Shibayama et al., 2006). These channels displayed a reduced occurrence in the residual state and a prolonged dwelling in the open state; very similar to C-terminally truncated Cx43 channels. These functional observations are underpinned by evidence from NMR studies showing that an L2 peptide in which His144 was changed into Glu displayed i) a decrease in the interaction with the C-terminal tail of Cx43 and ii) a disrupted secondary structure (Shibayama et al., 2006). In contrast to L2, the solution structure of




Fig. 3. Amino acid presentation of a Cx43-building block and its relevant regions for loop/tail and tail/tail interactions. The Cx43 building block contains different hot spots for loop/tail and tail/tail interactions. Residues in the C-terminal tail involved in binding the cytoplasmic loop are indicated with a red *, while the residues involved in C-terminal tail dimerization are indicated with a blue =. Four relevant Cx-mimetic peptide sequences are indicated: L2 (orange line), Gap19 (red line), SH3 (light blue line) and CT9 (dark blue line). In most cases, these peptides are fused to cell-penetrating sequences like TAT or antennapedia to facilitate cell-entry, except for Gap19, which displays endogenous cell-penetrating properties. The L2 region contains two His residues (His126 and His144; black circles) that are critical for forming α helices upon a decrease in pH and for binding the C-terminal tail. Residues Ile130 (blue circle) and Lys134 (green circle) seem important for interaction with the CT9 region, which contains different important residues, like Asp378 and Asp379 (green circles). These negatively charged residues are believed to be important for ionic interactions with positively charged residues in the L2 region, while other hydrophobic residues may be involved in non-ionic interactions with the L2 region. Furthermore Pro375 and Pro377 may contribute to the proper structural organization of these residues. This figure has been adapted from Lampe and Lau (2000). Reprinted from Archives of Biochemistry and Biophysics, 384(2), Paul D. Lampe and Alan F. Lau, Regulation of Gap Junctions by Phosphorylation of Cxs, 205–215, Copyright © 2000 Academic Press, with permission from Elsevier.

L2^{H144E} failed to form two α -helical regions at pH 5.8. Besides the role of the L2 region in channel closure upon acidosis, this region also seems important for proper channel-pore organization. Indeed, gap junctions formed by Cx43 carrying L2-subregion deletions caused a loss of electrical communications, despite their ability to form plaques (Seki et al., 2004a). Furthermore, the interaction between the loop and the C-terminal tail at low pH may also depend on homo-oligomerization, which is induced upon intracellular acidification (Hirst-Jensen et al., 2007). Different regions in the C-terminal tail are involved in the homodimerization of the C-terminal tail, including regions covered by amino acids 281–295, 299–304, 314–327, 340–348 and 364–382. These regions display considerable overlap with regions involved in the interaction with the cytoplasmic loop. Regions covered by amino acids 343–346 and 377–379 strongly contributed to cytoplasmic loop binding, while regions covered by amino acids 312–332, 335–340, 347–349, 357–361, 364–374 and 380–382 weakly contribute to cytoplasmic loop binding. Importantly, deletion of regions that affect homo-dimerizations also affects the binding of the cytoplasmic loop domain. Based on these findings, it was proposed that dimerization of the C-terminal tail upon low pH is critical for interaction with the cytoplasmic loop domain (Hirst-Jensen et al., 2007). Beyond its role in chemical gating of Cx43, the C-terminal tail regulates the localization, number and size of Cx43 plaques *in vivo*, probably through interaction with accessory proteins (Maass et al., 2007). These accessory proteins and post-translational modifications may also control the closure of Cx43 gap junction channels. For instance, binding of Src via its SH3 domain and SH2 domain to the proline-rich region and the phosphorylated Tyr265 residue of Cx43, respectively, leads to Src-mediated phosphorylation of Cx43 on Tyr247 (Kanemitsu et al., 1997). Mutations in the SH3-binding domain of Cx43 of Tyr265

result in defective Src binding and phosphorylation. Expression of Src and phosphorylation of Tyr247/265 disrupts Cx43-mediated gap junction communication between cells, but not in cells expressing Cx43^{Y265F} or Cx43 Δ 265 (Giepmans et al., 2001). Physiological Src signaling occurs downstream of G-protein-coupled receptor signaling, leading to the loss of cell to cell communication (Postma et al., 1998). Interestingly, the binding of Src to Cx43 is highly pH-dependent, being enhanced at low pH (Duffy et al., 2004). Another important binding partner of the C-terminal tail of Cx43 is the scaffolding protein ZO-1 (Giepmans and Moolenaar, 1998; Toyofuku et al., 1998), which stabilizes Cx43 gap junction channel formation (Giepmans and Moolenaar, 1998), determines the size of gap junctions (Hunter et al., 2005) and localization of gap junctions (Palatinus et al., 2011a), and regulates the rate of connexon docking (Rhett et al., 2011). Increased binding of constitutively active Src to Cx43 coincided with decreased Cx43/ZO-1-complex formation (Toyofuku et al., 2001). This interdependence is underpinned by the fact that the increased binding of Src to Cx43 at low pH also prevents and reversed the binding of ZO-1 to Cx43, resulting in ZO-1-stripped Cx43-gap junction channels (Duffy et al., 2004). As a consequence of this, the internalization of Cx43 gap junctions is enhanced. To summarize, intracellular acidification, as occurs during ischemia, leads to the closure of Cx43-based gap junction channels through an increased dimerization of the C-terminal tail and concomitant structural arrangement in the cytoplasmic domain of Cx43, resulting in a binding of the C-terminal tail to the cytoplasmic domain. In addition, low intracellular pH will result in the stripping of ZO-1 from Cx43 gap junction channels through the recruitment of Src, which facilitates the closure of Cx43 gap junction channels and ultimately results in an increased internalization of Cx43 gap junction channels and a reduced fraction of plasmalemmal Cx43 gap junctions. In any case, the C-

terminal tail, its binding partners and post-translational modifications are dispensable for the targeting and the formation of functional Cx43 gap junction channels (Hunter and Gourdie, 2008; Maass et al., 2007).

2.2. Loop and C-terminal tail Cx43-mimetic peptides and their effects on Cx43 gap junction channels

In this section, we provide a systematic overview of the different peptides and peptide-derived molecules that are based on intracellular Cx43 sequences proposed to be involved in loop/tail interactions. These peptides and peptide-derived molecules therefore are believed to target the critical regions in the cytoplasmic loop or C-terminal tail, thereby preventing the occurrence of “endogenous” Cx43 loop/tail interactions that result in the closure of Cx43 gap junction channels.

2.2.1. The SH3-binding domain peptide

A 17-mer peptide corresponding to amino acids 271–287 (CSSPTAPLSPMSPPGYK), which is the proline-rich region forming the SH3-binding domain for Src, was used as a molecule to interfere with the pH_i -dependent gating of Cx43 gap junction channels (Calero et al., 1998) (Fig. 3). Injection of this peptide in Cx43-expressing and pair-forming oocytes completely abolished the intracellular acidification-mediated closure of Cx43 gap junction channels, while normal pH_i -dependent gating was observed in cells injected with a scrambled version (Calero et al., 1998). The mechanism could involve different possibilities. The 17-mer peptide could act as the direct target for the receptor located in the cytoplasmic loop, thereby preventing the binding of the C-terminal tail to the loop. In addition, this 17-mer peptide also partially overlaps with regions responsible for C-terminal tail dimerization, an important step in the binding of the cytoplasmic loop and inhibition of Cx43 gap junction channels (Hirst-Jensen et al., 2007). Finally, this 17-mer peptide can also interfere with the recruitment of Src to Cx43 and the subsequent Tyr265 phosphorylation of Cx43 (known to inhibit Cx43 gap junction channels), thereby preventing Src-mediated Cx43 gap junction inhibition at low pH (Kanemitsu et al., 1997).

2.2.2. The C-terminal CT9 peptide

A 9-mer peptide corresponding to the last 9 amino acids of the C-terminal tail of Cx43 (CT9) has been developed (Fig. 3). This sequence has different biological properties, including binding to the cytoplasmic loop domain (Hirst-Jensen et al., 2007; Ponsaerts et al., 2010), binding to the PDZ-2 domain of ZO-1 (Hunter et al., 2005; Sorgen et al., 2004a) and increasing PKC- ϵ -mediated phosphorylation of Cx43 after left ventricular injury in a cryo-injury model (O’Quinn et al., 2011; Palatinus et al., 2011b). A cell-permeable version of the CT9 peptide, called ACT1, was developed by Gourdie and co-workers, serving as an inhibitor of ZO-1 interaction by targeting its PDZ2 domain (Hunter et al., 2005). ACT1 caused an increase in Cx43 gap junction size by facilitating the transfer from nonjunction Cx43 pools into gap junction plaques, a process that seems to be limited and tightly controlled by ZO-1 (Hunter et al., 2005). ACT1 decreased the interaction of Cx43 with ZO-1 at the perinexus, thereby increasing the presence of Cx43 as gap junctions and decreasing its presence as hemichannels (Palatinus et al., 2012; Rhatt and Gourdie, 2012). As a consequence of this shift in gap junction/hemichannel ratio, ACT1 increased Cx43 gap junction communication and decreased Cx43-hemichannel function. These effects were related to altered ZO-1 function, since ZO-1 knockdown recapitulated these effects of ACT1. Also, ACT1 seems to provide a relatively rapid shift in Cx43 gap junction partitioning, which occurred within 2 h of ACT1

exposure to cells (Rhatt et al., 2011). In any case, while these ACT1 effects on gap junctions seem to represent a remodeling of the amount of Cx43 gap junctions, it is clear that ACT1 does not inhibit Cx43 gap junction channel activity. The accumulation of Cx43 gap junctions upon ACT1 treatment seems to be beneficial for wound healing in a variety of conditions (Ghatnekar et al., 2009; Gourdie et al., 2006; Rhatt et al., 2008).

Very recently, ACT1 has been applied in a cryo-injury model of the left ventricle, which was proposed to be relevant for ventricular arrhythmias (O’Quinn et al., 2011). The latter has been associated with Cx43 gap junction remodeling, which also occurred in the wound and injury border zone. ACT1 exposure prevented Cx43 gap junction remodeling, thereby suppressing arrhythmic behavior of the heart and increasing ventricular depolarization rates up to 7–9 days after the injury. While control samples displayed an increased lateralization of Cx43 associated with Cx43 dephosphorylation, ACT1-treated samples displayed an improved accumulation of Cx43 at the intercalated disks. ACT1 partially prevented Cx43 dephosphorylation by increasing the PKC- ϵ -mediated phosphorylation of Ser368 of Cx43 at the wound and injury border zone. Interestingly, ACT1 also stimulated PKC- ϵ -mediated phosphorylation of recombinantly expressed and purified C-terminal tail of Cx43 *in vitro*, while PDZ2 of ZO-1 counteracted this process. These cardioprotective effects of ACT1 on Cx43 phosphorylation fits the earlier reports showing that PKC- ϵ prevented Cx43 gap junction remodeling during transient ischemia (Ek-Vitorin et al., 2006) or during global ischemia after ischemic pre-conditioning (Srisakuldee et al., 2009).

2.2.3. The L2 peptide

As discussed above, the L2 region in the cytoplasmic loop domain was shown to function as a receptor for the C-terminal tail (Duffy et al., 2002). Binding of the C-terminal tail to the L2 region is known to close Cx43 gap junction channels, like during low pH_i /ischemic conditions (Duffy et al., 2002; Ek-Vitorin et al., 1996; Morley et al., 1996). Based on these findings, a peptide corresponding to the L2 region of Cx43 (amino acids 119–144) has been developed (Seki et al., 2004b) (Fig. 3). Application of this peptide did not alter the unitary conductance of Cx43 gap junction channels, but decreased the frequency of transitions into the residual state, increased the open time and altered the voltage dependence of the Cx43 gap junction channels. These effects resembled the results obtained with Cx43^{M257}. Furthermore, the L2 peptide was also shown to bind the C-terminal tail of Cx43 at pH 6.5. A mutant L2 peptide (L2^{H126K/I130N}) was not able to bind Cx43’s C-terminal tail and did not affect Cx43 gap junction channel properties. These mutations, which occur in the region that corresponds to the first α -helix, likely disrupt the structural elements in this peptide needed for interaction with the C-terminal tail. In follow-up studies, another L2 mutant peptide was analyzed. L2^{H142E}, which lacked the second His critical for the formation of the second α -helix in the L2 peptide, failed to bind the C-terminal tail of Cx43 and modulate Cx43 gap junction channel properties in electrophysiological experiments (Shibayama et al., 2006). Thus, L2 peptides by preventing intramolecular loop/tail interactions seem to favor the open state of Cx43 gap junction channels in response to high transjunctional voltage ($\geq +60$ mV).

2.3. Non-Cx43-mimetic peptides modulating Cx43 gap junctions

2.3.1. RXP-E peptide

An unbiased peptide screen for binding the C-terminal tail of Cx43 resulted in the identification of novel peptides that could modulate Cx43 gap junctions by targeting intramolecular interactions (Shibayama et al., 2006). In particular, peptides

containing the RXP motif were found to preferably target the C-terminal tail of Cx43 (Shibayama et al., 2006). Further optimization studies resulted in an RXP-E peptide that binds the C-terminal tail of Cx43 with high affinity. Importantly, in electrophysiological experiments in N2a cells ectopically expressing Cx43, RXP-E increased the mean open time of Cx43 gap junction channels and partially prevented the closure of Cx43 gap junction channels in response to octanol or acidosis. Importantly, the effect of RXP-E on octanol-induced uncoupling of Cx43 gap junctions required the presence of the C-terminal tail of Cx43. Indeed, RXP-E was not able to alleviate the octanol-triggered uncoupling of Cx43^{M257}-based gap junctions, although there was a delay in octanol inhibition, suggesting an additional target outside the C-terminal tail of Cx43. NMR studies led to the identification of two RXP-E-binding regions in the C-terminal tail of Cx43, covering amino acids 343 to 346 (region 1) and 376–379 (region 2) (Shibayama et al., 2006). Importantly, region 1 has been found to be important for pH-dependent dimerization of the C-terminal tail of Cx43 (Sorgen et al., 2004b), while region 2 was identified as the PDZ-2-binding site of ZO-1 (Sorgen et al., 2004a). Thus, RXP-E peptide might be very potent, since it displays two separate molecular and biological properties, thereby interfering with intramolecular interactions underlying C-terminal tail dimerization and with intermolecular interactions underlying the recruitment of ZO-1. The effects of RXP-E were further assessed in monolayer cultures of cardiomyocytes isolated from neonatal and adult rats (Lewandowski et al., 2008), revealing that RXP-E i) was able to bind the cardiac Cx43, ii) alleviated Cx43 gap junction uncoupling upon heptanol and intracellular acidosis, and iii) prevented the block of action potential propagation upon intracellular acidosis. Further work resulted in the development of two novel pharmacophores, a cyclized heptapeptide (called CyRP-71) and a linear octapeptide of sequence RRNYRRNY, promoting Cx43 gap junction channel opening (Verma et al., 2009). The identification of the core structural elements in the RXP-E peptide (RRXY) has spurred the development of the first peptidomimetic molecule, AcRRK(4-HO-Benzoyl)-NH₂, called ZP2519, that prevented the closure of Cx43 gap junctions upon heptanol exposure or intracellular acidosis by targeting the C-terminal tail of Cx43 (Verma et al., 2010).

2.3.2. AAP10 and ZP123

About twenty years ago, a synthetic peptide called AAP10 (GAG-4Hyp-PY-CONH₂) was found to display anti-arrhythmic effects (Dhein et al., 1994) and this could be linked to effects on Cx43 expression and function via a PKC-dependent mechanism (De Vuyst et al., 2011; Easton et al., 2009; Hagen et al., 2009; Herve and Dhein, 2006). AAP10 is based on the natural anti-arrhythmic peptide AAPnat (H-Gly-Pro-Hyp-Gly-Ala-Gly) that was isolated from bovine atria and further synthetically improved (Dhein et al., 1994; Grover and Dhein, 2001). Application of AAP10 (even at very low concentration of 10 and 50 nM) enhanced gap junction conductance in adult guinea pig cardiomyocytes, which are predominantly coupled via Cx43 and in HeLa cells ectopically expressing Cx43 (Weng et al., 2002). The stimulatory effect of AAP10 on gap junction conductance was dependent on PKC α activity. AAP10 enhanced the activity of PKC α , thereby promoting PKC α -dependent phosphorylation of Cx43. These peptides were further used to counteract Cx43 gap junction remodeling in heart failure models. For instance, acute hypoxia in rat hearts leads to a decrease in Cx43 expression, reduced Cx43 phosphorylation and redistribution of Cx43 from gap junctions into intracellular pools, resulting in decreased gap junction communication (Wang et al., 2007). AAP10 prevented Cx43 dephosphorylation during acute hypoxia and increased total Cx43 levels (mainly in the phosphorylated form), thereby preventing shut down of gap junction communication in the heart. In acute

regional myocardial ischemia, AAP10 prevented the decrease in Cx43 phosphorylation in the ischemic region, but had no effect on Cx43 phosphorylation in the non-ischemic region (Jozwiak and Dhein, 2008). The decrease in Cx43 phosphorylation was associated with Cx43 redistribution in the ischemic zone, which could be prevented by AAP10 treatment. However, peptides based on L-amino acids display a poor stability in *in vivo* systems. Therefore, a new anti-arrhythmic peptide was developed, ZP123 (rotigapeptide), representing a retro-all-D-amino acid design of the AAP10 template (Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH₂) (Dhein et al., 2003; Wit and Duffy, 2008). ZP123 too enhanced Cx43 gap junction conductance in a PKC α -dependent manner, but with enhanced enzymatic stability in *in vivo* applications. Consistent with its positive effect on gap junction conductance, rotigapeptide also prevented the closure of gap junction channels by acidosis (Eloff et al., 2003), thereby maintaining intercellular coupling, diminishing the slowing down of conduction velocity and the heterogeneity in repolarization. All these influences contribute to anti-arrhythmic effects. Rotigapeptide also preserved the conduction of the atria during metabolic stress (Haugan et al., 2005) and upon atrial fibrillation (Guerra et al., 2006; Shiroshita-Takeshita et al., 2007). In open-chest dogs undergoing ischemia/reperfusion and rats with chronic myocardial infarction, spontaneous arrhythmias and infarct size were reduced by rotigapeptide treatment (Haugan et al., 2006; Hennen et al., 2006). Again, these effects likely are due to maintained Cx43 phosphorylation (e.g. at Ser297 and Ser368), which is indeed to form functional gap junction channels (Axelsen et al., 2006). Interestingly, rotigapeptide has been applied to explanted heart from end-stage heart failure patients and resulted in an improved conduction velocity (Wiegerinck et al., 2009). However, in healing infarct border zone partial reversal of Cx43 remodeling seemed not be sufficient to restore normal conduction or prevent arrhythmias (Macia et al., 2011).

3. Intramolecular loop/tail interactions are essential for Cx43-hemichannel opening

3.1. Cx43 hemichannels and gap junction channels display opposite outcomes to signaling molecules

There is increasing evidence from several labs that gap junctions and hemichannels may be influenced in an opposite manner by signaling molecules or intracellular events. For instance, it is well established that metabolic inhibition associated with ischemia/reperfusion lead to closure of Cx43 gap junction channels in the heart (Duffy et al., 2004; Johansen et al., 2011; Severs, 1994), while promoting the opening of Cx43 hemichannels, resulting in ionic leakage, intracellular Ca²⁺ and Na⁺ overload and cell death (Johansen et al., 2011; John et al., 1999; Kondo et al., 2000; Li et al., 2001; Shintani-Ishida et al., 2007). Cytokines, like interleukin-1 β (IL-1 β) and tumor necrosis factor- α (TNF- α) are released by microglia under inflammatory conditions (Kettenmann et al., 2011; Simi et al., 2007) inhibit Cx43 gap junctions, thereby reducing intercellular communication between astrocytes while enhancing Cx43-hemichannel activity, thereby increasing plasma membrane permeability (Retamal et al., 2007a). The latter is based on strong evidence using Cx43-knockout mice and Cx43-hemichannel inhibitors. Interestingly, opposite functional outcomes of cytokines on Cx43 gap junctions and hemichannels were mediated by a common p38 mitogen activated protein kinase pathway. The effects of cytokines on Cx43 hemichannels were dependent on sulfhydryl oxidation reactions on Cx43, since reducing agents like dithiothreitol counteracted these effects. Moreover, these cytokines also resulted in increased Cx43-hemichannel activity, despite the reduction in the total and surface-available Cx43 levels upon

cytokine treatment. The latter finding is supported by electrophysiological experiments showing that the unitary events of ~220 pS corresponding to Cx43 hemichannels were much more frequent in cytokine-treated astrocytes. Other studies found similar oppositely directed effects on gap junctions and hemichannels. For instance, an augmented level of intracellular oxidative stress (e.g. during ischemia/reperfusion) decreased Cx43-mediated gap junction communication, but at the same time increased Cx43-hemichannel activity by increasing the open probability and the number of surface Cx43 hemichannels (Retamal et al., 2006, 2007b, c). Again, this mechanism seemed to depend on changes in the intracellular redox state, which may modulate Cx43 hemichannels by influencing the three intracellular Cys residues present on the C-terminal tail. In C6 glioma cells ectopically expressing Cx43, some kinase-activating stimuli, like the immunostimulating lipopolysaccharide (LPS) and basic fibroblast growth factor (bFGF), have been described to cause the inhibition of Cx43 gap junction channels, while stimulating the release of ATP via Cx43 hemichannels (De Vuyst et al., 2007). An independent study from Saez and co-workers clearly underpinned these findings, showing that fibroblast growth factor-1 (FGF-1), which is released in spinal cord injury, caused permeabilization and ATP release of spinal cord astrocytes (Garre et al., 2010). This ATP release was at least in part through the opening of Cx43 hemichannels (besides vesicular ATP release and Panx-mediated ATP release). In contrast, interastrocyte coupling through Cx43 gap junctions was inhibited. These mechanisms may further promote inflammation and to contribute to the loss of protective effects of astrocytes on neurons. In any case, there seems ample evidence that Cx43-based gap junction channels and hemichannels are oppositely regulated, as recently highlighted by the differential action of growth factors on gap junctions and hemichannels (Schalper et al., 2012).

3.2. Loop and C-terminal tail modifications differentially affect Cx43 gap junctions and hemichannels

Besides the evidence at the physiological level that Cx43-based gap junction channels and hemichannels display opposite responses upon cellular signaling events, there are also a number of molecular studies exploiting the expression of truncated, C-terminally tagged or mutated Cx43 proteins (Fig. 4). These studies point towards critical differences in the dependence of gap




Fig. 4. TAT-CT10 is sufficient to restore the activity of C-terminally truncated Cx43 hemichannels. C-terminally truncated Cx43 hemichannels cannot be opened in response to stimuli like an increase in intracellular $[Ca^{2+}]_i$. Yet, the addition of the last 10 amino acids is sufficient to open C-terminally truncated Cx43 hemichannels in response to an increase in intracellular $[Ca^{2+}]_i$. It is important to note that the peptide by itself is not sufficient to open the C-terminally truncated Cx43 hemichannels in the absence of stimuli. For clarity reasons, the monomeric building blocks are depicted, but it should be noted that the functional channel unit is hexameric.

junction channels versus hemichannels to intramolecular loop/tail interactions for their activity. i) C-terminally truncated Cx43 is able to form functional gap junction channels (De Vuyst et al., 2007; Maass et al., 2007), which are even resistant to closure upon intracellular acidosis (Morley et al., 1996). In contrast, C-terminally truncated Cx43 hemichannels fail to form functional hemichannels. The latter is supported by different types of evidence. In electrophysiological experiments using cell-attached patches and inside-out patches on C6 glioma cells ectopically expressing Cx43, the opening of Cx43 hemichannels could be detected and analyzed (Kang et al., 2008). However, truncating Cx43 at Met257 resulted in loss of Cx43 hemichannel activity and single-channel openings were not observed. This is further supported by other studies, showing that cells ectopically expressing Cx43^{M239} or Cx43^{M257} display strongly reduced ATP release triggered by decreasing extracellular $[Ca^{2+}]_o$ using the Ca^{2+} buffer EGTA (De Vuyst et al., 2007) or by increasing intracellular $[Ca^{2+}]_i$ using the Ca^{2+} ionophore A23187 (De Vuyst et al., 2009; Ponsaerts et al., 2010) (Fig. 4). ii) GFP-tagging of Cx43 at its C-terminal tail resulted in an increase of the gap junction-plaque size, and a potentiation of gap junction communication (Bukauskas et al., 2000; Hunter et al., 2003; Verselis and Bukauskas, 2002). Cx43-GFP-based hemichannels may display altered gating. For instance, they only displayed slow gating between the fully closed and the fully open state while the fast gating from the residual state to the fully open state disappeared (Contreras et al., 2003; Kang et al., 2008). These data correlate with the compromised ATP-flux properties of Cx43-GFP-based hemichannels (Kang et al., 2008). Yet, brief openings of the Cx43 hemichannels might occur as ethidium bromide uptake was observed in Cx43-GFP-expressing cells (Contreras et al., 2003). The latter has been confirmed in studies showing that lowering the intracellular redox potential or exposing cells to FGF-1 promotes the opening of Cx43 and Cx43-EGFP-based hemichannels (Retamal et al., 2007b; Schalper et al., 2008). However, in a very recent study showing whole-cell recordings on single non-connected Cx43-EGFP-expressing HeLa cells, membrane depolarizations above +40 mV led to unitary events associated with the opening of Cx43 hemichannels as characterized by their typical single-channel conductance of ~220 pS (Wang et al., 2013a). These direct electrophysiological recordings of unitary currents seem to indicate that the fusion of EGFP to the C-terminal tail of Cx43 does not alter its single-channel properties. In any case, the influence of GFP tagged to the C-terminal tail of Cx43 on endogenous loop/tail interactions in Cx43 hemichannels ought to be further established. iii) Pathological mutations in the L2 region of Cx43 have been identified in patients suffering from oculodentodigital dysplasia. For instance, Cx43^{G138R} and Cx43^{G143S} were found to be deficient in gap junction coupling, while ATP-releasing hemichannel activity was promoted (Dobrowolski et al., 2007). Hence, these mutations, which occur in the L2 region, differentially affect Cx43 gap junctions and hemichannels. Thus, these data indicate that while Cx43 gap junctions are closed by intramolecular loop/tail interactions, e.g. during intracellular acidosis (Ek-Vitorin et al., 1996), Cx43 hemichannels actually depend on intramolecular loop/tail interactions for their opening in response to cellular stimuli (Ponsaerts et al., 2010). Yet, at this stage, it is not clear whether these intramolecular loop/tail interactions in Cx43 hemichannels are pre-established (even in the absence of cellular stimuli) or whether stimuli that increase Cx43-hemichannel opening (like depolarization, low extracellular $[Ca^{2+}]_o$ or moderate rises in intracellular $[Ca^{2+}]_i$) do it by triggering the binding of the C-terminal tail to the intracellular loop. It is thus conceivable that these cellular stimuli trigger conformational changes in the Cx43-building blocks that facilitate the binding and subsequent opening of the Cx43

hemichannels or that only the conformation of Cx43 hemichannels in which loop/tail interactions are established allows to sense the stimuli, resulting in the opening of Cx43 hemichannels. The latter option definitely is possible, since we found that the L2 region was able to bind the C-terminal tail of Cx43 at physiological pH (Ponsaerts et al., 2010). In any case, we postulate that the binding of the C-terminal tail to the intracellular loop is not sufficient for the opening of Cx43 hemichannels, but requires an additional activating stimulus.

3.3. Intracellular loop peptides inhibit Cx43 hemichannels but not gap junction channels

As discussed above, the L2 region in Cx43 acts as a receptor for the C-terminal tail, which functions as a gating particle, underlying the closure of gap junction channels during acidosis (Duffy et al., 2002; Seki et al., 2004b). Synthetic L2 peptides promote the opening of Cx43 gap junction channels (Duffy et al., 2002; Seki et al., 2004b; Shibayama et al., 2006). Making use of the cell-permeable TAT-coupled L2 peptide, we found that the L2 peptide inhibited the opening of Cx43 hemichannels in response to an extracellular $[Ca^{2+}]$ decrease or an intracellular $[Ca^{2+}]$ increase without affecting gap junction coupling (Evans et al., 2012; Ponsaerts et al., 2010) (Figs. 1 and 3). TAT-L2 inhibited Cx43-hemichannel-mediated ATP release in response to a $[Ca^{2+}]$ increase brought about by 2 μM Ca^{2+} ionophore with an IC50 of about 10 μM . Further studies led to the identification of a non-peptide variant of L2 peptide that displayed a certain degree of endogenous cell-penetrating potential (Gap19) (Evans et al., 2012; Wang et al., 2013b) (Fig. 3). The Gap19 peptide covers the region between amino acids 128 and 136. Gap19 provoked Cx43-hemichannel inhibition with an IC50 of about 50 μM , while not blocking Cx43 gap junction channels (Wang et al., 2013b). Coupling Gap19 to TAT facilitated its cell-penetrating properties and provoked inhibition of Cx43-hemichannel responses with an IC50 of less than 10 μM . Furthermore, Gap19 was selective for Cx43-based hemichannels, since it had no effect on Cx40- and Panx1-based hemichannels. These findings were supported by electrophysiological experiments, demonstrating that Gap19 inhibit Cx43 hemichannel unitary currents in both HeLa cells exogenously expressing Cx43 and acutely isolated pig ventricular cardiomyocytes. Thus, Gap19 inhibition of Cx43 hemichannel opening, activated by voltage, is likely the result of a shift of the activation potential of hemichannel opening to more positive potentials. Consistent with previous reports, we found that biotinylated versions of L2 and Gap19 were able to bind the C-terminal tail of Cx43, expressed and purified as a recombinant protein, in surface plasmon resonance experiments (Wang et al., 2013b). Thus, it seems that the binding of the C-terminal tail of Cx43 hemichannels to its endogenous L2 receptor region in Cx43 is an absolute requirement for the opening of Cx43 hemichannels. Preventing this binding using TAT-L2 or Gap19 resulted in the inhibition of Cx43-hemichannel opening. Furthermore, a stretch of nine amino acids within the L2 region seem to serve as a hot spot for the interaction of the C-terminal tail, carrying critical elements for intramolecular loop/tail-complex formation. Interestingly, the amino acids present in Gap19 are largely positively charged (KQIEIKKFK), thereby contributing to its intrinsic cell-penetrating properties. Critical amino acids in Gap19 were I130 and K134, since mutating these residues into Ala disrupted its ability to inhibit Cx43 hemichannels. The influence of K134A mutation on Gap19 function was tested in a mammalian expressing plasmid encoding Flag-Gap19. The critical role of K134 fits well with the presumed binding site at the C-terminal tail, namely the last nine amino acids, in which negatively charged Asp residues have been

implicated in establishing loop/tail binding via ionic interactions (Hirst-Jensen et al., 2007). Additionally, the critical role of I130 in Gap19 in the inhibition of Cx43 hemichannels fits well with presumed structural integrity that is needed at this site to form α -helical structures (Duffy et al., 2002). In addition, I130 may contribute to the binding of the C-terminal tail via non-ionic interactions. Consistent with these findings, Gap19^{I130A} was much less efficient in inhibiting Cx43 hemichannel unitary currents in Cx43-expressing HeLa cells and adult pig cardiomyocytes containing endogenous high levels of Cx43 (Wang et al., 2013b).

Finally, since cell-penetrating Cx43-loop peptides selectively inhibit Cx43 hemichannels without blocking Cx43 gap junction channels, they are ideal tools to target Cx43 hemichannels in complex cellular systems or to demonstrate the contribution of Cx43 hemichannels in cellular signaling processes (Evans et al., 2012). In particular, traditional knockout or knockdown approaches prevent the expression of the Cx43 building blocks, thereby affecting both Cx43 gap junction and hemichannels. As a control for TAT-L2, it is recommended to use TAT-L2^{H126K/I130N}, a mutated version of TAT-L2 that is not able to bind the C-terminal tail of Cx43 and thus does not interfere with loop/tail interactions.

3.4. C-terminal tail peptides restore the activity of Cx43^{M239} hemichannels

As discussed above, Cx43^{M239} hemichannels fail to open in response to conditions that stimulate Cx43-hemichannel opening. Strikingly, we found that a short peptide sequence covering the last 10 amino acids of the C-terminal tail (TAT-CT10) was sufficient to restore the activity of Cx43 hemichannels that lack their complete C-terminal tail (Ponsaerts et al., 2010). This was supported by ATP release assays in Cx43^{M239}-expressing C6 glioma and HeLa cells. Further evidence was provided by electrophysiological measurements in *Xenopus* oocytes, in which endogenous Cx38 was knocked down and ectopic Cx43 was expressed (Ponsaerts et al., 2010). Consistent with the original report showing that in *Xenopus* oocytes expression of Cx43, in contrast to Cx46, does not induce depolarization, lysis, permeability to Lucifer yellow and voltage-gated currents in non-junctional membranes (Paul et al., 1991), we confirmed that Cx43 is not able to form functional hemichannels in *Xenopus* oocytes (Ponsaerts et al., 2010). We have proposed that the strong cortical actin cytoskeleton prevents the binding of the C-terminal tail to the cytoplasmic loop domain, thereby hampering the opening of Cx43 hemichannels (Ponsaerts et al., 2012b). Strikingly, TAT-CT10 was able to overcome this inherent lack of loop/tail interactions, thereby restoring the activity of Cx43 hemichannels as determined in electrophysiology experiments in *Xenopus* oocytes exogenously expressing Cx43 (Ponsaerts et al., 2010). The negative regulation of Cx43-hemichannel activity by the actin cytoskeleton via disrupting essential loop/tail interactions has been further underpinned by a variety of experimental approaches. Thrombin treatment of corneal endothelial cells inhibits Cx43-hemichannel-driven intercellular Ca^{2+} -wave propagation via the cytoskeleton, since (–)-blebbistatin could alleviate this inhibitory effect (Ponsaerts et al., 2008). Pre-incubating corneal endothelial cells with TAT-CT10 completely alleviated thrombin-induced inhibition of Cx43 hemichannels (Ponsaerts et al., 2010). Similarly, C6 or HeLa cells ectopically expressing Cx43 display a bell-shaped dependence towards intracellular $[Ca^{2+}]$, with $[Ca^{2+}]$ below 500 nM triggering Cx43-hemichannel opening and with $[Ca^{2+}]$ above 500 nM inhibiting Cx43-hemichannel opening (De Vuyst et al., 2009). The inhibition of Cx43 hemichannels by high intracellular $[Ca^{2+}]$ could be completely alleviated by (–)-blebbistatin (Ponsaerts et al., 2010). In contrast, pre-incubating the cells with TAT-CT10 completely prevented the inhibition of Cx43 hemichannels by high intracellular

[Ca²⁺] (Ponsaerts et al., 2010). Correlating with this, TAT-CT10 restored the activity of Cx43^{M239} hemichannels, while (–)-blebbistatin did not. Thus, it seems that the last 10 amino acids of the C-terminal tail harbor residues that are critical for loop/tail interactions in Cx43 hemichannels. Hence, these findings reinforce the necessity for the C-terminal tail of Cx43 for Cx43-hemichannel activity (Ponsaerts et al., 2010). Moreover, these effects of TAT-CT10 were independent of its ability to bind the PDZ-2 domain of ZO-1. Indeed, TAT-CT10ΔI, lacking the last isoleucine residue essential for the binding of the PDZ-2 domain of ZO-1 (Giepmans and Moolenaar, 1998), was equally potent in i) restoring the activity of Cx43^{M239}-based hemichannels and ii) alleviating the inhibition of Cx43-based hemichannels by high intracellular [Ca²⁺] (Ponsaerts et al., 2010). At the biochemical level, we demonstrated that a biotinylated version of CT10 and CT10ΔI was able to interact with the L2 region of Cx43 but not with the L2^{H126K/I130N} variant (Ponsaerts et al., 2010). Finally, while CT10 binding to L2 is required for the opening of Cx43 hemichannels, it is not sufficient by itself to induce Cx43-hemichannel opening (Ponsaerts et al., 2010). Indeed, TAT-CT10, by itself, did not open Cx43^{M239} hemichannels in the absence of stimuli like low extracellular [Ca²⁺] or increased intracellular [Ca²⁺].

Very recently, we identified the residues in TAT-CT10 critical for its activity to regulate Cx43 hemichannels (D'hondt et al., 2013). We found that mutating Asp378 and Asp379 into Ala residues abolished TAT-CT10's ability to alleviate the inhibition of Cx43 hemichannels by high intracellular [Ca²⁺] and to restore Cx43^{M239}-hemichannel activity in response to moderate rises in intracellular [Ca²⁺]. Similar results were obtained by mutating Pro375 and Pro377 into Gly residues. On the other hand, mutating Arg374 and Arg376 into Ala residues did not alter the functional properties of TAT-CT10 on Cx43 hemichannels. Thus, it seems that at least negatively charged Asp residues and their proper structural organization via Pro residues are critical determinants to establish loop/tail interactions involving the CT10 region.

3.5. Cell-permeable loop peptides and C-terminal tail peptides neutralize each other's action

Finally, the inhibition of Cx43 hemichannels by TAT-L2 or Gap19 can be completely neutralized by co-incubating the cells with TAT-CT10 (Ponsaerts et al., 2010; Wang et al., 2013b). Consistent with the importance of ionic and non-ionic interactions, the neutralization of Gap19's inhibitory properties on Cx43 hemichannels by TAT-CT10 was dependent on the presence of two Pro residues (amino acids 375 and 377) and two Asp residues (amino acids 378 and 379) (Wang et al., 2013b). The importance of these residues in the CT10 sequence for binding the cytoplasmic loop domain ought to be further examined in *in vitro* binding experiments, like surface plasmon resonance. *Vice versa*, the ability of TAT-CT10 to overcome the inhibition of Cx43 hemichannels in response to high intracellular [Ca²⁺] is ablated by co-incubating the cells with TAT-L2 (Ponsaerts et al., 2010). These findings are mechanistically supported by the ability of biotin-CT10 immobilized to a streptavidin-coated sensor chip to bind TAT-L2 in *in vitro* binding experiments based on surface plasmon resonance.

3.6. Applications of cell-permeable loop and C-terminal tail peptides to tackle Cx43 hemichannel functions in complex cellular systems and pathophysiological conditions

3.6.1. L2

There has been increasing evidence from *in vitro* and *ex vivo* studies that astrocytes are involved in synaptic plasticity and may contribute to synaptic activity via the release of neuroactive

gliotransmitter substances, including D-serine, glutamate, and ATP (Fellin et al., 2006; Scolari and Acosta, 2007; Verkhratsky and Parpura, 2010; Volterra and Meldolesi, 2005). In addition, glutamate released from astroglial cells has been shown to affect neurotransmitter release at the synaptic cleft (Santello et al., 2012). Unfortunately, due to the lack of selective Cx43-hemichannel inhibitors and the fact that Cx43-knockout animals lack both gap junction channels and hemichannels, the role of Cx43 hemichannels in the release of gliotransmitters from astrocytes and their relevance for the control of higher brain function *in vivo* is still an open question (Stehberg et al., 2012). Recently, we exploited the biophysical properties of TAT-L2 to assess whether Cx43 hemichannels are involved in the release of gliotransmitters under *in vivo* conditions. This approach was possible because this peptide did not affect the neuronal components of synaptic transmission, which do not express Cx43, nor did the peptide influence gap junction coupling between neighboring astrocytes. The TAT-L2 peptide was micro-injected in the basolateral amygdala, a region of the brain involved in the processing of emotion, more specifically fear and fear memory (Stehberg et al., 2012). Using an auditory fear conditioning training protocol (a conditioned sound stimulus shortly followed by an unconditioned electrical shock stimulus), proper memory consolidation was assessed 24 h after the training by providing the conditioned sound stimulus only (Stehberg et al., 2012). Strikingly, TAT-L2, but not TAT-L2^{H126K/I130N}, completely and potently blocked fear memory consolidation and provoked a complete amnesia towards the auditory fear conditioning. Concentrations as low as 10 nM TAT-L2 proved to be effective in triggering amnesia. These effects of TAT-L2 were transitory and did not affect the short-term memory aspects of the fear conditioning paradigm. Also, the amnesic effects of TAT-L2 were only provoked when administered during the period of memory consolidation (within the first 4 h after the auditory fear conditioning training protocol). Moreover, inhibition of fear memory by TAT-L2 disappeared by supplementing TAT-L2 with an exogenous cocktail of putative gliotransmitters (including glutamate, glutamine, lactate, D-serine, glycine, and ATP). These data demonstrate the potential of TAT-L2 as a tool to help unraveling the contribution of Cx43 hemichannels in complex biological systems like the brain.

3.6.2. Gap19

Gap19 is a nonapeptide variant of TAT-L2 that displays intrinsic cell-penetrating activities and selectively inhibits Cx43 hemichannels (Fig. 2) (Evans et al., 2012; Wang et al., 2013b). Importantly, Gap19 (100 μM) strongly inhibited unitary Cx43-hemichannel currents in freshly isolated cardiomyocytes (Wang et al., 2013b). Moreover, Gap19 also inhibited the promotion of unitary hemichannels currents when the cardiomyocytes were subject to metabolic inhibition by applying a combination of mitochondrial uncoupler and a glycolysis inhibitor (chemical inhibition) (Wang et al., 2013b). This was further tested both *in vitro* and *in vivo* in ischemia, which is known to promote deleterious Cx43-hemichannel activity in a redox and phosphorylation-dependent manner (Wang et al., 2013b). In those experiments, it was hypothesized that excessive opening of Cx43 hemichannels results in cell death due to the loss of energy, ionic and metabolic gradients (Evans et al., 2006). In freshly isolated cardiomyocytes, addition of Gap19 before exposure to oxygen-glucose deprivation/acidosis followed by reperfusion, improved the cell viability and prevented cell swelling (Wang et al., 2013b). Importantly, Gap19^{I130A} was much less potent than Gap19 in suppressing cell death and swelling. Finally, in *in vivo* myocardial ischemia/reperfusion applied to mice by ligation of the left anterior descending coronary artery followed by reperfusion, Gap19, but not Gap19^{I130A} (250 μM, added 10 min before ligation), significantly reduced the

infarct size. These are promising observations, indicating that the opening of Cx43 hemichannels in the plasma membrane may indeed contribute to ischemia/reperfusion damage in the heart. It is essential here to underscore the fact that gap junction channels are not inhibited by Gap19; in the heart but also in the brain, inhibition of gap junctions would result in significant confounding effects, making interpretation of the experimental results problematic. Hence, Gap19 inhibition of Cx43 hemichannels, combined with work on the Cx43^{G138R} mutant that is linked to promoted hemichannel activity (Dobrowolski et al., 2007) offers an interesting set of tools to explore the role of Cx43 hemichannels in various physiological and pathological conditions. Moreover, Gap19 and L2 peptides not only have specificity toward hemichannels, but also toward the specific type of Cx. Indeed, the sequences mimicked by these peptides are located on the cytoplasmic loop of the Cx protein; these sequences are very different between different Cx types. In line with this, we found that Gap19 blocked Cx43 hemichannels but not those composed of Cx40 or Panx1 (Wang et al., 2013b).

3.6.3. CT peptides

TAT-CT10 is a cell-permeable peptide that corresponds to the last 10 amino acids of the C-terminal tail of Cx43 and prevents the inhibition of Cx43 hemichannels by high intracellular $[Ca^{2+}]$ (Ponsaerts et al., 2010). This correlates with previous findings showing that the high intracellular $[Ca^{2+}]$ -mediated inhibition of Cx43 hemichannels can be alleviated by using i) TAT-CT10ΔI, which lacks the last isoleucine (Ponsaerts et al., 2010) or ii) the CT9 peptide, which corresponds to the last 9 amino acids of the C-terminal tail and does not contain Ser373 (De Bock et al., 2012). CT9 is not cell-permeable and ought to be loaded in intact cells via other means, like electroporation approaches (De Vuyst et al., 2008) or cationic lipid-mediated transfer. Furthermore, it is important to note that ACT1, developed by Gourdie and co-workers, corresponds to the CT9 sequence, but linked to a different cell-penetrating motif that is based on the antennapedia sequence (Hunter et al., 2005; O'Quinn et al., 2011). Thus, TAT-CT10, CT9 and ACT1 converge by sharing the last 9 amino acids of the C-terminal tail of Cx43, harboring the critical elements for binding the L2 region in Cx43 hemichannels. Table 1 provides an overview of the sequences of these peptides.

Recently, CT9 has been used to assess the contribution of Cx43 hemichannels to sustain agonist-induced Ca^{2+} oscillations (De Bock et al., 2012). It was found that Ca^{2+} oscillations triggered by bradykinin, but not those triggered by extracellular ATP, were dependent on Cx hemichannels. These two agonists, and the associated two different Ca^{2+} oscillation mechanisms and patterns, appeared to also have a differential effect on the permeability of blood–brain barrier endothelial cells, with bradykinin increasing the permeability and ATP having no effect (De Bock et al., 2011). Using CT9 peptide and other peptides mimicking extracellular loop domains (Gap26 and/or Gap27), it was found that i) Ca^{2+} entry via Cx43 hemichannels is essential in bradykinin-triggered Ca^{2+} oscillations, and ii) the bell-shaped dependence of Cx43 hemichannels to intracellular $[Ca^{2+}]$ is critical sustain Ca^{2+} oscillations. Thus, Ca^{2+} signals from the ER will rise cytosolic $[Ca^{2+}]$ above 100 nM, thereby opening Cx43 hemichannels and providing a Ca^{2+} influx pathway

(De Vuyst et al., 2009). As a result, cytosolic $[Ca^{2+}]$ will further rise till 500 nM and higher, which will lead to the closure of Cx43 hemichannels and closure of the Ca^{2+} entry pathway. It is interesting to note that IP₃Rs too display a bell-shaped dependence to intracellular $[Ca^{2+}]$ in the similar range as for Cx43 hemichannels, with low cytosolic $[Ca^{2+}]$ being stimulatory and high cytosolic $[Ca^{2+}]$ being inhibitory (Bezprozvanny et al., 1991; Iino, 1990). Finally, consistent with our previous findings showing that interactions between the CT peptides and the L2 region were independent of the last isoleucine and that inhibition of Cx43 hemichannels too could be alleviated by TAT-CT10ΔI (Ponsaerts et al., 2010), CT9ΔI too disrupted bradykinin-induced Ca^{2+} oscillations (De Bock et al., 2012). Thus, the effects of the CT peptides on Ca^{2+} oscillations are not due to the disruption of Cx43/ZO-1 interactions. In fact, ZO-1 may mainly bind to Cx43 gap junctions and not hemichannels, as we failed to detect ZO-1 co-immunoprecipitation with Cx43 hemichannels (Ponsaerts et al., 2010).

3.6.4. Therapeutic applications for selective Cx43-hemichannel inhibitors

Definitely, given the emerging role of Cx43 in the spreading of cell death (Decrock et al., 2009a,b, 2011, 2012), TAT-L2 and derived peptides (like Gap19) and other small inhibitory molecules have therapeutic potential in ischemia/reperfusion injury in the brain or heart. They may reduce tissue damage from excessive cell death and its spread, by limiting excessive Cx43-hemichannel opening, while maintaining gap junction coupling. Importantly, Gap19 reduced the detrimental outcome of ischemia/reperfusion in isolated cardiomyocytes *in vitro* and in the heart *in vivo*. This further highlights the therapeutic potential of inhibiting Cx43 hemichannels and underpins the favorable outcomes obtained with other Cx-mimetic and -inhibiting peptides, Gap26 and Gap27. For instance, Gap26 administered before or after the occurrence of ischemia or as single intravenous low-dose injections protected the intact heart against ischemia-reperfusion injury (Hawat et al., 2010, 2012). Likely, therapeutic applications of L2/Gap19 peptide or like molecules are not limited to the heart, but could also be neuroprotective. For instance, Peptide5 which is mimetic peptide that overlaps with the Gap27 domain, displayed protective effects against detrimental events following retinal ischemia/reperfusion, including a reduction in endothelial cell death, reduced vascular leakage and increased retinal ganglion cell survival in the injured retina (Danesh-Meyer et al., 2012). Inhibition of Cx43 hemichannels is also favorable to reduce inflammation by suppressing the release of inflammatory cytokines and to prevent secondary tissue damage by suppressing neuronal death after cerebral or spinal cord injuries (Huang et al., 2012; O'Carroll et al., 2008, 2013). Mechanistically, inflammatory cytokines released from microglia, like IL-1β and TNF-α, increase astrocytic Cx43-hemichannel activity (Retamal et al., 2007a). The latter will be responsible for post-traumatic ATP release, which will result in neuronal death through the activation of Panx1 (Orellana et al., 2011a) and which has been implicated in aggravated secondary injury and restrained functional recovery (Huang et al., 2012). Thus, inhibition of excessive astrocytic Cx43-hemichannel activity in response to inflammatory cytokine released from microglia upon injury has neuroprotective

Table 1
An overview of the different C-terminal Cx43 peptides. All peptides contain a common sequence that corresponds to the last 9 amino acids of the C-terminal tail of Cx43. The underlined sequence corresponds to the cell-penetrating motif that is fused to the Cx43 sequence (Antennapedia for ACT1 and TAT for TAT-CT10).

Peptide name	Peptide sequence	Developed by	References
ACT1	<u>RQPKLWFPNRRKPWKRRPRPDDLEI</u>	Gourdie and co-workers	(Hunter et al., 2005; O'Quinn et al., 2011)
TAT-CT10	<u>YGRKKRRQRRRSRPRPDDLEI</u>	Bultynck, Leybaert and co-workers	(Ponsaerts et al., 2010)
CT9	<u>RPRPDDLEI</u>	Bultynck, Leybaert and co-workers	(De Bock et al., 2012)

potential (Froger et al., 2010). In particular, L2/Gap19-derived tools might be preferentially used over Gap26/Gap27 Cx-mimetic peptides, since L2/Gap19 may be useful to counteract the concomitant inhibition of metabolic coupling due to gap junction inhibition observed during many of these conditions (Meme et al., 2006; Retamal et al., 2007a).

L2/Gap19 or derived molecules might also be useful in other types of injury. For instance, the cryopreservation/thawing process of arteries and veins affects the integrity of the intimal layer and the cell viability of the endothelial cells. Application of Gap27 that targets both Cx43 and Cx37 channels during the cryopreservation/thawing process significantly improves the conservation of the intimal layers and reduces cell death in the endothelial cells as well as smooth muscle cells. Hence, TAT-L2 (or Gap19) as a selective Cx43 inhibitor could also be used. Yet, since other Cx isoforms are expressed in the vasculature that are not targeted by TAT-L2 (or Gap19), like Cx37, the use of TAT-L2 (or Gap19) as a single agent would likely be insufficient.

Moreover, the application of these peptide tools may not be limited to counteract damage or injury by ischemia/reperfusion, but may also be relevant for neurodegenerative diseases, like Alzheimer's disease. Amyloid β not only potentiates the action of inflammatory cytokines released from microglia on astrocytic Cx43 hemichannels (Meme et al., 2006), but may also increase the presence of Cx43 on the cell surface (Mei et al., 2010). Amyloid β has been proposed to trigger a "toxic" signaling cascade that is driven by hemichannel activation in glial and neuronal cells. Thus, inflammatory cytokines from microglia may promote the release of glutamate and ATP through glial (microglia and astrocytes) hemichannels, thereby triggering the deleterious opening of neuronal hemichannels and resulting in neuronal cell death. Thus, L2/Gap19 or derived peptides may provide unprecedented avenues to prevent the toxic Cx43-hemichannel activity in glial cells, thereby promoting the survival of neuronal cells in the presence of A β (Orellana et al., 2011b).

Finally, beyond neurodegenerative diseases, L2/Gap19 or derived molecules might be applicable to interfere with the essential role of Cx43 hemichannels in the release of gliotransmitters during fear memory consolidation (Stehberg et al., 2012). As such, tools that selectively inhibit Cx43 hemichannels may provide a novel strategy for the future treatment of psychiatric disorders, including anxiety and post-traumatic stress disorders.

3.7. Concerns associated with the use of peptides targeting Cx43 hemichannels

While these peptide tools are particularly useful in biological research, it is important to note that there are a number of limitations associated with their use.

3.7.1. Stability

As for all peptides composed of natural amino acids, it is important to realize that these peptides might be unstable and/or degraded upon prolonged cellular incubations, thereby losing their activity. Yet, it seems that these peptide sequences remain quite stable at least for hours (Ponsaerts et al., 2010). For instance, prolonged incubation of Gap19 for 24–48 h in Cx43-expressing C6-glioma cells promoted dye coupling using FRAP experiments, while completely blocking ATP release in response to moderate intracellular [Ca²⁺] rises (Wang et al., 2013b). Regarding potential clinical uses, the peptides are likely to be degraded rapidly, limiting their usability to only short and localized therapeutic applications. Additionally, the peptides are expected to nonspecifically bind plasma components when administered via the I.V. route.

3.7.2. Selectivity

Another concern is the selectivity of these Cx43-hemichannel-modulating peptides towards other Cx and/or Panx isoforms. While a complete profile of the effect of these peptides on other Cx and Panx isoforms has not been performed, it is important to consider that the sequences corresponding to the L2 (and Gap19) region and the CT10 region are hyper variable sequences with very low homology between the different Cx and Panx isoforms. This is also evident from Table 2, which provides an overview of the results obtained from a BLAST search using the human Cx43 sequence. Even Cx isoforms closely related to Cx43 (like Cx37, Cx46, Cx40, Cx50 and Cx62) display a very high heterogeneity in their "L2 sequence", while some resemblance of the "CT10" sequence of Cx43 could only be found in Cx46 and Cx40. Thus, from this analysis, it is very unlikely that TAT-L2 and Gap19, which target the CT10 region in Cx43, will affect other Cx-based hemichannels, although this ought to be scrutinized for Cx46- and Cx40-based hemichannels. Yet, our recent experiments indicate a critical role for the two Pro residues in the CT10 region of Cx43 to establish interactions with the intracellular loop region and these Pro residues do not seem to be present in the CT10 region of Cx46 and Cx40 (D'hondt et al., 2013). Also the TAT-CT10 peptides likely display a high selectivity towards Cx43 hemichannels, given the very low resemblance of the L2/Gap19 region between Cx43 and other Cx isoforms. Not only sequence analysis seems to hint toward Cx43-selective tools, but also experimental analysis supports this claim. For instance, Gap19, in contrast to the established Panx1-inhibitory peptide ¹⁰Panx1, did not inhibit Panx1-mediated ATP release from C6-glioma cells ectopically expressing Panx1 in response to high extracellular [K⁺] (Wang et al., 2013b). Gap19 also did not affect Cx40-hemichannel-mediated ATP release in response to elevated intracellular [Ca²⁺] (Wang et al., 2013b). On the other hand, we found that a peptide corresponding to the sequence of the L2 region in Cx50 did not affect Cx43-hemichannel-driven intercellular Ca²⁺-wave propagation (Ponsaerts et al., 2010).

Table 2

BLAST results obtained by searching database UniProtKB/Swiss-Prot (swissprot) using PSI-BLAST (Position-Specific Iterated BLAST) by entering the human Cx43 sequence and limiting the output to human sequences (Altschul et al., 1997). The table only shows the regions corresponding to the L2 (Gap19 sequence is underlined) and CT10 region of human Cx43.

L2 region of closely related Cx isoforms	
Cx43	DGVNVD <u>MHLKQIEIKKFKY</u> GIEEHGK
Cx37	KDPQVERALAAIERQMAKISVAEDGR
Cx46	SPSPKEPPQDNPNSSR-----DDRGR
Cx50	AGTNGGP--DQGSVKK-SSGSKGTKK
Cx40	SGSYEYPVAEKAEELSCWEEG---NGR
Cx62	ENPDLDLEE <u>QQRELR</u> LEEQKRIH-K RID
CT10 region of closely related Cx isoforms	
Cx43	SRPRPDDLEI
Cx37	
Cx46	SRARPEDLAI
Cx50	
Cx40	---RSDDLVS
Cx62	

3.7.3. Incomplete inhibition

At the electrophysiological level, the unitary currents provoked by Cx43 hemichannels in Hela-Cx43 cells or ventricular cardiomyocytes were severely reduced by Gap19 incubation but were not completely inhibited, even not at high concentrations (Wang et al., 2013b). This is in contrast with the experiments that assess Cx43-hemichannel function by measuring ATP release, intercellular Ca^{2+} wave propagation and dye uptake, showing that Gap19 (and L2 peptide) impose a complete inhibition of these responses (Ponsaerts et al., 2010; Wang et al., 2013b). Thus, the passage of large signaling molecules (like ATP, which has a molecular weight of 507 Da) may be more affected by these peptide tools than ions. This is in line with previous observations, showing that PKC-dependent phosphorylation of Cx43 hemichannels restricts the passage of sucrose (molecular weight of 342 Da) but not that of ethyleneglycol (molecular weight of 62) (Bao et al., 2007). Alternatively, the inhibition of ATP release by Gap19 and L2 might reflect a non-linear event, since a 50% reduction of the Cx43 levels is sufficient to completely prevent ATP release (De Vuyst et al., 2009).

3.7.4. High concentrations

The TAT-L2, Gap19 and TAT-CT10/CT9 peptide tools require relatively high concentrations to induce their effects on Cx43 hemichannels. In most of our experiments, 100 μ M of TAT-L2 or TAT-CT10/CT9 was needed to achieve complete effects (Ponsaerts et al., 2010). TAT-L2 inhibited Cx43-hemichannel-mediated ATP release with an IC₅₀ of about 11 μ M, while TAT-CT10 restored Cx43^{M239}-hemichannel-mediated ATP release with an EC₅₀ of about 10 μ M (Ponsaerts et al., 2010). This likely reflects four aspects: i) the efficiency of cell-entry of these tools; ii) the distribution of these peptides inside the cells with likely a major part of these peptides accumulating in sites/compartments devoid of Cx43 hemichannels; iii) the binding of these peptides to the distinct Cx43 regions; and iv) the low intrinsic affinity of intramolecular loop/tail interactions. In *in vitro* experiments, EC₅₀ values of about 3 μ M were obtained for the binding of the C-terminal tail of Cx43 to biotin-L2 and biotin-Gap19 (Wang et al., 2013b). Thus, the relatively high IC₅₀ values (about 50 μ M) obtained for native Gap19 to inhibit Cx43-mediated ATP release likely reflect its sub-optimal cell-entry properties (Wang et al., 2013b). Consistent with this, improving Gap19's cell-entry properties by coupling it to the TAT sequence significantly lowered this IC₅₀ value (Wang et al., 2013a,b; see supplementary material). In any case, the use of proper control peptides like inactive mutants (TAT-L2^{H126K/I130N}, Gap19^{I130A}, or TAT-CT10^{D377A/D378A}) or scrambled/reversed sequence peptides are essential to assess non-specific effects. Further support for the increase in cell-entry properties by the use of peptide coupling with TAT sequence comes from *in vivo* experiments, where TAT-L2 micro-injected into the basolateral amygdala had significant amnesic effects in memory consolidation when injecting as low as 10 nM of TAT-L2 (Stehberg et al., 2012). Although it is technically challenging to evaluate the effects of the peptide on Cx43 hemichannel opening *in vivo*, the physiological effectiveness of TAT-L2 at 10 nM, while TAT-L2^{H126K/I130N} was without effect, ascertains the peptide's direct actions on Cx43 hemichannels and rules out pleiotropic effects. Also, these data suggest that a decrease in Cx43 hemichannel activity can have important physiological effects without necessarily requiring the complete silencing of the hemichannels.

4. Perspectives and conclusions

Thus, it is clear that intramolecular interactions between the C-terminal tail and the cytoplasmic loop of Cx43 critically control the activity of gap junction channels and hemichannels but with a different outcome. In gap junctions occurs the binding of the C-

terminal tail to the cytoplasmic loop during pathological conditions like acidosis, leading to the closure of gap junction channels. In contrast, in hemichannels, the binding of the C-terminal tail to the cytoplasmic loop is essential for the opening of Cx43 hemichannels in response to different cellular stimuli, including increases in cytosolic $[Ca^{2+}]$ in the physiological range (between 100 nM and 500 nM). Interestingly, the same molecular determinants underlie loop/tail binding in gap junctions and hemichannels, including at least the L2 region as the receptor and the CT10 region as part of the particle. As a consequence, peptides targeting these regions seem to provoke opposite effects. For instance, TAT-L2 promotes gap junction channel opening and prevents its closure during acidosis and inhibits hemichannel opening in response to cellular stimuli. This opens novel scientific and therapeutic perspectives to use TAT-L2 and peptide variants to selectively inhibit Cx43 hemichannels while maintaining Cx43 gap junction channels. Therefore, TAT-L2 and its nonapeptide variant Gap19 can be used as a selective Cx43-hemichannel inhibitor in cellular models and organs to pinpoint the contribution of Cx43 hemichannels in cell biological and physiological processes. In the brain and the heart, these peptides can be applied to counteract excessive hemichannel activity during ischemia/reperfusion or metabolic inhibition, while sustaining gap junction communication, essential for action potential spreading in the heart or glucose spreading within astrocyte layers. Furthermore, the recently discovered role of Cx43 hemichannels in fear memory consolidation highlights the potential of TAT-L2/Gap19 as attractive lead compounds to tackle various psychiatric and neurological disorders where excessive hemichannel function is part of the pathophysiological problem.

Nevertheless, a number of questions remain about intramolecular loop/tail interactions regulating Cx43 hemichannels. For instance, it is not known whether in analogy to gap junction channels other regions in the C-terminal tail besides the CT10 amino acid stretch are involved in binding to the L2 receptor region. It is also not clear how binding of the C-terminal tail to the cytoplasmic loop leads to opening of Cx43 hemichannels but closure of Cx43 gap junction channels. This likely involves differences in conformation between undocked hemichannels and head-to-head-docked gap junction channels, pointing to an important role for the extracellular loops. Moreover, it is not clear whether the C-terminal tail is always bound to the cytoplasmic loop or whether the binding is induced upon exposure to stimuli like strong depolarization, extracellular Ca^{2+} buffers or intracellular Ca^{2+} -mobilizing agents. In any case, since Cx43 hemichannels can permeate Ca^{2+} and thus influence intracellular $[Ca^{2+}]$ and intracellular $[Ca^{2+}]$ influence Cx43-hemichannel opening, it will be critical to assess the role of intracellular Ca^{2+} in loop/tail interactions. Ca^{2+} may directly affect the conformation of the cytoplasmic loop or C-terminal tail, thereby altering their binding properties, or may indirectly affect loop/tail interactions through Ca^{2+} -binding proteins, like calmodulin, which binds near the L2 region or through Ca^{2+} -dependent phosphorylation/dephosphorylation processes. In addition, intracellular Ca^{2+} may also alter the ability of C-terminal tail to dimerize, an essential step in binding L2 in gap junctions. Yet, the importance of C-terminal tail dimerization for the opening Cx43 hemichannels or rendering them in an activatable state remains elusive. Finally, until now, all of our evidence has been obtained with Cx43 hemichannels, but it is not clear whether hemichannels formed by other Cx isoform too are controlled by loop/tail interactions. A likely candidate that might be controlled by loop/tail interactions is Cx32, since Cx32 hemichannels too display a bell-shaped dependence towards intracellular $[Ca^{2+}]$ (De Vuyst et al., 2006).

In conclusion, loop/tail interactions in Cx43 involving the L2 and CT10 regions are an important switch that turns off Cx43 gap junction channels, while turning on Cx43 hemichannels, leading to

opposite outcomes. These interactions can be exploited by Cx43-mimetic peptides that target these hot spots for interactions, thereby leading to unprecedented opportunities to inhibit Cx43 hemichannels while maintaining Cx43 gap junction coupling.

Acknowledgments

The authors thank their lab members for helpful discussions. GB wants to thank Dr. Rob Gourdie for helpful discussions on the ACT1 peptide. Work performed in the authors' laboratory was supported by research grants from the Research Foundation-Flanders (F.W.O. grant: G.0298.11 to L.L. and G.B.), Interuniversity Attraction Poles Program (Belgian Science Policy, project P7/10 to L.L., and P7/13 to G.B.), Universidad Andrés Bello (UNAB) (grant UNAB DI-02-11/N (to J.S.)), and by Anillo ACT1104 and Fondecyt 1120214 (to M.A.R.). C.D.H. is supported by a post-doctoral fellowship from the Research Foundation-Flanders (F.W.O.).

References

- Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, D.J., 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25, 3389–3402.
- Ambrosi, C., Gassmann, O., Pranskevich, J.N., Boassa, D., Smock, A., Wang, J., Dahl, G., Steinem, C., Sosinsky, G.E., 2010. Pannexin1 and Pannexin2 channels show quaternary similarities to connexons and different oligomerization numbers from each other. *J. Biol. Chem.* 285, 24420–24431.
- Axelsen, L.N., Stahlhut, M., Mohammed, S., Larsen, B.D., Nielsen, M.S., Holstein-Rathlou, N.H., Andersen, S., Jensen, O.N., Hennan, J.K., Kjolbye, A.L., 2006. Identification of ischemia-regulated phosphorylation sites in connexin43: a possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). *J. Mol. Cell. Cardiol.* 40, 790–798.
- Bao, X., Lee, S.C., Reuss, L., Altenberg, G.A., 2007. Change in permeant size selectivity by phosphorylation of connexin 43 gap-junctional hemichannels by PKC. *Proc. Natl. Acad. Sci. U.S.A.* 104, 4919–4924.
- Bezprozvanny, I., Watras, J., Ehrlich, B.E., 1991. Bell-shaped calcium-response curves of Ins(1,4,5)P₃- and calcium-gated channels from endoplasmic reticulum of cerebellum. *Nature* 351, 751–754.
- Billaud, M., Sandilos, J.K., Isakson, B.E., 2012. Pannexin 1 in the regulation of vascular tone. *Trends Cardiovasc. Med.* 22, 68–72.
- Bukauskas, F.F., Jordan, K., Bukauskiene, A., Bennett, M.V., Lampe, P.D., Laird, D.W., Verselis, V.K., 2000. Clustering of connexin 43-enhanced green fluorescent protein gap junction channels and functional coupling in living cells. *Proc. Natl. Acad. Sci. U.S.A.* 97, 2556–2561.
- Calero, G., Kanemitsu, M., Taffet, S.M., Lau, A.F., Delmar, M., 1998. A 17mer peptide interferes with acidification-induced uncoupling of connexin43. *Circ. Res.* 82, 929–935.
- Chandrasekhar, A., Bera, A.K., 2012. Hemichannels: permeants and their effect on development, physiology and death. *Cell Biochem. Funct.* 30, 89–100.
- Contreras, J.E., Saez, J.C., Bukauskas, F.F., Bennett, M.V., 2003. Gating and regulation of connexin 43 (Cx43) hemichannels. *Proc. Natl. Acad. Sci. U.S.A.* 100, 11388–11393.
- D'hondt, C., Iyyathurai, J., Wang, N., Gourdie, R.G., Himpens, B., Leybaert, L., Bultynck, G., 2013. Negatively charged residues (Asp378 and Asp379) in the last ten amino acids of the C-terminal tail of Cx43 hemichannels are essential for loop/tail interactions. *Biochem. Biophys. Res. Commun.* 432, 707–712.
- D'hondt, C., Ponsaerts, R., De Smedt, H., Bultynck, G., Himpens, B., 2009. Pannexins, distant relatives of the connexin family with specific cellular functions? *Bioessays* 31, 953–974.
- D'hondt, C., Ponsaerts, R., De Smedt, H., Vinken, M., De Vuyst, E., De Bock, M., Wang, N., Rogiers, V., Leybaert, L., Himpens, B., Bultynck, G., 2011. Pannexin channels in ATP release and beyond: an unexpected rendezvous at the endoplasmic reticulum. *Cell. Signal.* 23, 305–316.
- Danesh-Meyer, H.V., Kerr, N.M., Zhang, J., Eady, E.K., O'Carroll, S.J., Nicholson, L.F., Johnson, C.S., Green, C.R., 2012. Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. *Brain* 135, 506–520.
- De Bock, M., Culot, M., Wang, N., Bol, M., Decrock, E., De Vuyst, E., da Costa, A., Dauwe, I., Vinken, M., Simon, A.M., Rogiers, V., De Ley, G., Evans, W.H., Bultynck, G., Dupont, G., Cecchelli, R., Leybaert, L., 2011. Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. *J. Cereb. Blood Flow Metab.* 31, 1942–1957.
- De Bock, M., Wang, N., Bol, M., Decrock, E., Ponsaerts, R., Bultynck, G., Dupont, G., Leybaert, L., 2012. Connexin 43 hemichannels contribute to cytoplasmic Ca²⁺-oscillations by providing a bimodal Ca²⁺-dependent Ca²⁺ entry pathway. *J. Biol. Chem.* 287, 12250–12266.
- De Vuyst, E., Boengler, K., Antoons, G., Sipido, K.R., Schulz, R., Leybaert, L., 2011. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. *Br. J. Pharmacol.* 163, 469–483.
- De Vuyst, E., De Bock, M., Decrock, E., Van Moorhem, M., Naus, C., Mabilde, C., Leybaert, L., 2008. In situ bipolar electroporation for localized cell loading with reporter dyes and investigating gap junctional coupling. *Biophys. J.* 94, 469–479.
- De Vuyst, E., Decrock, E., Cabooter, L., Dubyak, G.R., Naus, C.C., Evans, W.H., Leybaert, L., 2006. Intracellular calcium changes trigger connexin 32 hemichannel opening. *EMBO J.* 25, 34–44.
- De Vuyst, E., Decrock, E., De Bock, M., Yamasaki, H., Naus, C.C., Evans, W.H., Leybaert, L., 2007. Connexin hemichannels and gap junction channels are differentially influenced by lipopolysaccharide and basic fibroblast growth factor. *Mol. Biol. Cell.* 18, 34–46.
- De Vuyst, E., Wang, N., Decrock, E., De Bock, M., Vinken, M., Van Moorhem, M., Lai, C., Culot, M., Rogiers, V., Cecchelli, R., Naus, C.C., Evans, W.H., Leybaert, L., 2009. Ca²⁺ regulation of connexin 43 hemichannels in C6 glioma and glial cells. *Cell Calcium* 46, 176–187.
- Decrock, E., De Bock, M., Wang, N., Gadicherla, A.K., Bol, M., Delvaeye, T., Vandenamee, P., Vinken, M., Bultynck, G., Krysko, D.V., Leybaert, L., 2013. IP(3), a small molecule with a powerful message. *Biochim. Biophys. Acta* 1833, 1772–1786.
- Decrock, E., De Vuyst, E., Vinken, M., Van Moorhem, M., Vranckx, K., Wang, N., Van Laeken, L., De Bock, M., D'Herde, K., Lai, C.P., Rogiers, V., Evans, W.H., Naus, C.C., Leybaert, L., 2009a. Connexin 43 hemichannels contribute to the propagation of apoptotic cell death in a rat C6 glioma cell model. *Cell Death Differ.* 16, 151–163.
- Decrock, E., Krysko, D.V., Vinken, M., Kaczmarek, A., Crispino, G., Bol, M., Wang, N., De Bock, M., De Vuyst, E., Naus, C.C., Rogiers, V., Vandenamee, P., Erneux, C., Mammano, F., Bultynck, G., Leybaert, L., 2012. Transfer of IP(3) through gap junctions is critical, but not sufficient, for the spread of apoptosis. *Cell Death Differ.* 19, 947–957.
- Decrock, E., Vinken, M., Bol, M., D'Herde, K., Rogiers, V., Vandenamee, P., Krysko, D.V., Bultynck, G., Leybaert, L., 2011. Calcium and connexin-based intercellular communication, a deadly catch? *Cell Calcium* 50, 310–321.
- Decrock, E., Vinken, M., De Vuyst, E., Krysko, D.V., D'Herde, K., Vanhaecke, T., Vandenamee, P., Rogiers, V., Leybaert, L., 2009b. Connexin-related signaling in cell death: to live or let die? *Cell Death Differ.* 16, 524–536.
- Delmar, M., Makita, N., 2012. Cardiac connexins, mutations and arrhythmias. *Curr. Opin. Cardiol.* 27, 236–241.
- Dhein, S., Larsen, B.D., Petersen, J.S., Mohr, F.W., 2003. Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. *Cell Commun. Adhes.* 10, 371–378.
- Dhein, S., Manicone, N., Muller, A., Gerwin, R., Ziskoven, U., Irankhahi, A., Minke, C., Klaus, W., 1994. A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. *Naunyn Schmiedebergers Arch. Pharmacol.* 350, 174–184.
- Dobrowolski, R., Sommershof, A., Willecke, K., 2007. Some oculodentodigital dysplasia-associated Cx43 mutations cause increased hemichannel activity in addition to deficient gap junction channels. *J. Membr. Biol.* 219, 9–17.
- Duffy, H.S., Ashton, A.W., O'Donnell, P., Coombs, W., Taffet, S.M., Delmar, M., Spray, D.C., 2004. Regulation of connexin43 protein complexes by intracellular acidification. *Circ. Res.* 94, 215–222.
- Duffy, H.S., Sorgen, P.L., Girvin, M.E., O'Donnell, P., Coombs, W., Taffet, S.M., Delmar, M., Spray, D.C., 2002. pH-dependent intramolecular binding and structure involving Cx43 cytoplasmic domains. *J. Biol. Chem.* 277, 36706–36714.
- Easton, J.A., Petersen, J.S., Martin, P.E., 2009. The anti-arrhythmic peptide AAP10 remodels Cx43 and Cx40 expression and function. *Naunyn Schmiedebergers Arch. Pharmacol.* 380, 11–24.
- Ek-Vitorin, J.F., Calero, G., Morley, G.E., Coombs, W., Taffet, S.M., Delmar, M., 1996. PH regulation of connexin43: molecular analysis of the gating particle. *Biophys. J.* 71, 1273–1284.
- Ek-Vitorin, J.F., King, T.J., Heyman, N.S., Lampe, P.D., Burt, J.M., 2006. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. *Circ. Res.* 98, 1498–1505.
- Ek, J.F., Delmar, M., Perzova, R., Taffet, S.M., 1994. Role of histidine 95 on pH gating of the cardiac gap junction protein connexin43. *Circ. Res.* 74, 1058–1064.
- Eloff, B.C., Gilat, E., Wan, X., Rosenbaum, D.S., 2003. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. *Circulation* 108, 3157–3163.
- Evans, W.H., Bultynck, G., Leybaert, L., 2012. Manipulating connexin communication channels: use of peptidomimetics and the translational outputs. *J. Membr. Biol.* 245, 437–449.
- Evans, W.H., De Vuyst, E., Leybaert, L., 2006. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. *Biochem. J.* 397, 1–14.
- Fellin, T., Sul, J.Y., D'Ascenzo, M., Takano, H., Pascual, O., Haydon, P.G., 2006. Bidirectional astrocyte-neuron communication: the many roles of glutamate and ATP. *Novartis Found Symp.* 276, 208–217 (discussion 217–221, 233–207, 275–281).
- Froger, N., Orellana, J.A., Calvo, C.F., Amigou, E., Kozoriz, M.G., Naus, C.C., Saez, J.C., Giaume, C., 2010. Inhibition of cytokine-induced connexin43 hemichannel activity in astrocytes is neuroprotective. *Mol. Cell. Neurosci.* 45, 37–46.
- Garre, J.M., Retamal, M.A., Cassina, P., Barbeito, L., Bukauskas, F.F., Saez, J.C., Bennett, M.V., Abudara, V., 2010. FGF-1 induces ATP release from spinal astrocytes in culture and opens pannexin and connexin hemichannels. *Proc. Natl. Acad. Sci. U.S.A.* 107, 22659–22664.

- Ghatnekar, G.S., O'Quinn, M.P., Jourdan, L.J., Gurjarpadhye, A.A., Draughn, R.L., Gourdie, R.G., 2009. Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. *Regen. Med.* 4, 205–223.
- Giepmans, B.N., Hengeveld, T., Postma, F.R., Moolenaar, W.H., 2001. Interaction of c-Src with gap junction protein connexin-43. Role in the regulation of cell-cell communication. *J. Biol. Chem.* 276, 8544–8549.
- Giepmans, B.N., Moolenaar, W.H., 1998. The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein. *Curr. Biol.* 8, 931–934.
- Gourdie, R.G., Ghatnekar, G.S., O'Quinn, M., Rhett, M.J., Barker, R.J., Zhu, C., Jourdan, J., Hunter, A.W., 2006. The unstoppable connexin43 carboxyl-terminus: new roles in gap junction organization and wound healing. *Ann. N.Y. Acad. Sci.* 1080, 49–62.
- Grover, R., Dhein, S., 2001. Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration. *Peptides* 22, 1011–1021.
- Gu, H., Ek-Vitorin, J.F., Taffet, S.M., Delmar, M., 2000. Coexpression of connexins 40 and 43 enhances the pH sensitivity of gap junctions: a model for synergistic interactions among connexins. *Circ. Res.* 86, E98–E103.
- Guerra, J.M., Everett, T.H., Lee, K.W., Wilson, E., Olgin, J.E., 2006. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. *Circulation* 114, 110–118.
- Hagen, A., Dietze, A., Dhein, S., 2009. Human cardiac gap-junction coupling: effects of antiarrhythmic peptide AAP10. *Cardiovasc. Res.* 83, 405–415.
- Haugan, K., Marcussen, N., Kjolbye, A.L., Nielsen, M.S., Hennan, J.K., Petersen, J.S., 2006. Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction. *J. Cardiovasc. Pharmacol.* 47, 236–242.
- Haugan, K., Olsen, K.B., Hartvig, L., Petersen, J.S., Holstein-Rathlou, N.H., Hennan, J.K., Nielsen, M.S., 2005. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. *J. Cardiovasc. Electrophysiol.* 16, 537–545.
- Hawat, G., Benderdour, M., Rousseau, G., Baroudi, G., 2010. Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. *Pflugers Arch.* 460, 583–592.
- Hawat, G., Helie, P., Baroudi, G., 2012. Single intravenous low-dose injections of connexin 43 mimetic peptides protect ischemic heart in vivo against myocardial infarction. *J. Mol. Cell. Cardiol.* 53, 559–566.
- Hennan, J.K., Swillo, R.E., Morgan, G.A., Keith Jr., J.C., Schaub, R.G., Smith, R.P., Feldman, H.S., Haugan, K., Kantrowitz, J., Wang, P.J., Abu-Qare, A., Butera, J., Larsen, B.D., Crandall, D.L., 2006. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. *J. Pharmacol. Exp. Ther.* 317, 236–243.
- Herve, J.C., Bourmeyster, N., Sarrouilhe, D., Duffy, H.S., 2007. Gap junctional complexes: from partners to functions. *Prog. Biophys. Mol. Biol.* 94, 29–65.
- Herve, J.C., Derangeon, M., 2013. Gap-junction-mediated cell-to-cell communication. *Cell. Tissue Res.* 352, 21–31.
- Herve, J.C., Dhein, S., 2006. Pharmacology of cardiovascular gap junctions. *Adv. Cardiol.* 42, 107–131.
- Herve, J.C., Dhein, S., 2010. Peptides targeting gap junctional structures. *Curr. Pharm. Des.* 16, 3056–3070.
- Hirst-Jensen, B.J., Sahoo, P., Kieken, F., Delmar, M., Sorgen, P.L., 2007. Characterization of the pH-dependent interaction between the gap junction protein connexin43 carboxyl terminus and cytoplasmic loop domains. *J. Biol. Chem.* 282, 5801–5813.
- Homma, N., Alvarado, J.L., Coombs, W., Stergiopoulos, K., Taffet, S.M., Lau, A.F., Delmar, M., 1998. A particle-receptor model for the insulin-induced closure of connexin43 channels. *Circ. Res.* 83, 27–32.
- Huang, C., Han, X., Li, X., Lam, E., Peng, W., Lou, N., Torres, A., Yang, M., Garre, J.M., Tian, G.F., Bennett, M.V., Nedergaard, M., Takano, T., 2012. Critical role of connexin 43 in secondary expansion of traumatic spinal cord injury. *J. Neurosci.* 32, 3333–3338.
- Hunter, A.W., Barker, R.J., Zhu, C., Gourdie, R.G., 2005. Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion. *Mol. Biol. Cell* 16, 5686–5698.
- Hunter, A.W., Gourdie, R.G., 2008. The second PDZ domain of zonula occludens-1 is dispensable for targeting to connexin 43 gap junctions. *Cell Commun. Adhes.* 15, 55–63.
- Hunter, A.W., Jourdan, J., Gourdie, R.G., 2003. Fusion of GFP to the carboxyl terminus of connexin43 increases gap junction size in HeLa cells. *Cell Commun. Adhes.* 10, 211–214.
- Iino, M., 1990. Biphasic Ca²⁺ dependence of inositol 1,4,5-trisphosphate-induced Ca release in smooth muscle cells of the guinea pig taenia caeci. *J. Gen. Physiol.* 95, 1103–1122.
- Ishikawa, M., Iwamoto, T., Nakamura, T., Doyle, A., Fukumoto, S., Yamada, Y., 2011. Pannexin 3 functions as an ER Ca(2+) channel, hemichannel, and gap junction to promote osteoblast differentiation. *J. Cell Biol.* 193, 1257–1274.
- Johansen, D., Cruciani, V., Sundset, R., Ytrehus, K., Mikalsen, S.O., 2011. Ischemia induces closure of gap junctional channels and opening of hemichannels in heart-derived cells and tissue. *Cell. Physiol. Biochem.* 28, 103–114.
- John, S.A., Kondo, R., Wang, S.Y., Goldhaber, J.L., Weiss, J.N., 1999. Connexin-43 hemichannels opened by metabolic inhibition. *J. Biol. Chem.* 274, 236–240.
- Johnstone, S.R., Billaud, M., Lohman, A.W., Taddeo, E.P., Isakson, B.E., 2012. Post-translational modifications in connexins and pannexins. *J. Membr. Biol.* 245, 319–332.
- Jozwiak, J., Dhein, S., 2008. Local effects and mechanisms of antiarrhythmic peptide AAP10 in acute regional myocardial ischemia: electrophysiological and molecular findings. *Naunyn Schmiedebergs Arch. Pharmacol.* 378, 459–470.
- Kanemitsu, M.Y., Loo, L.W., Simon, S., Lau, A.F., Eckhart, W., 1997. Tyrosine phosphorylation of connexin 43 by v-Src is mediated by SH2 and SH3 domain interactions. *J. Biol. Chem.* 272, 22824–22831.
- Kang, J., Kang, N., Lovatt, D., Torres, A., Zhao, Z., Lin, J., Nedergaard, M., 2008. Connexin 43 hemichannels are permeable to ATP. *J. Neurosci.* 28, 4702–4711.
- Kar, R., Batra, N., Riquelme, M.A., Jiang, J.X., 2012. Biological role of connexin intercellular channels and hemichannels. *Arch. Biochem. Biophys.* 524, 2–15.
- Kettenmann, H., Hanisch, U.K., Noda, M., Verkhratsky, A., 2011. Physiology of microglia. *Physiol. Rev.* 91, 461–553.
- Kondo, R.P., Wang, S.Y., John, S.A., Weiss, J.N., Goldhaber, J.L., 2000. Metabolic inhibition activates a non-selective current through connexin hemichannels in isolated ventricular myocytes. *J. Mol. Cell. Cardiol.* 32, 1859–1872.
- Lampe, P.D., Lau, A.F., 2000. Regulation of gap junctions by phosphorylation of connexins. *Arch. Biochem. Biophys.* 384, 205–215.
- Lewandowski, R., Prociada, K., Vaidyanathan, R., Coombs, W., Jalife, J., Nielsen, M.S., Taffet, S.M., Delmar, M., 2008. RXP-E: a connexin43-binding peptide that prevents action potential propagation block. *Circ. Res.* 103, 519–526.
- Leybaert, L., Sanderson, M.J., 2012. Intercellular Ca(2+) waves: mechanisms and function. *Physiol. Rev.* 92, 1359–1392.
- Li, F., Sugishita, K., Su, Z., Ueda, I., Barry, W.H., 2001. Activation of connexin-43 hemichannels can elevate [Ca(2+)]_i and [Na(+)]_i in rabbit ventricular myocytes during metabolic inhibition. *J. Mol. Cell. Cardiol.* 33, 2145–2155.
- Liu, S., Taffet, S., Stoner, L., Delmar, M., Vallano, M.L., Jalife, J., 1993. A structural basis for the unequal sensitivity of the major cardiac and liver gap junctions to intracellular acidification: the carboxyl tail length. *Biophys. J.* 64, 1422–1433.
- Loiselle, A.E., Jiang, J.X., Donahue, H.J., 2013. Gap junction and hemichannel functions in osteocytes. *Bone* 54, 205–212.
- Maass, K., Shibayama, J., Chase, S.E., Willecke, K., Delmar, M., 2007. C-terminal truncation of connexin43 changes number, size, and localization of cardiac gap junction plaques. *Circ. Res.* 101, 1283–1291.
- Macia, E., Dolmatova, E., Cabo, C., Sosinsky, A.Z., Dun, W., Coromilas, J., Ciaccio, E.J., Boyden, P.A., Wit, A.L., Duffy, H.S., 2011. Characterization of gap junction remodeling in epicardial border zone of healing canine infarcts and electrophysiological effects of partial reversal by rotigaptide. *Circ. Arrhythm. Electrophysiol.* 4, 344–351.
- Mei, X., Ezan, P., Giaume, C., Koulakoff, A., 2010. Astroglial connexin immunoreactivity is specifically altered at beta-amyloid plaques in beta-amyloid precursor protein/presenilin1 mice. *Neuroscience* 171, 92–105.
- Meme, W., Calvo, C.F., Froger, N., Ezan, P., Amigou, E., Koulakoff, A., Giaume, C., 2006. Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid. *FASEB J.* 20, 494–496.
- Miro-Casas, E., Ruiz-Meana, M., Agullo, E., Stahlhofen, S., Rodriguez-Sinovas, A., Cabestrero, A., Jorge, I., Torre, I., Vazquez, J., Boengler, K., Schulz, R., Heusch, G., Garcia-Dorado, D., 2009. Connexin43 in cardiomyocyte mitochondria contributes to mitochondrial potassium uptake. *Cardiovasc. Res.* 83, 747–756.
- Morley, G.E., Taffet, S.M., Delmar, M., 1996. Intramolecular interactions mediate pH regulation of connexin43 channels. *Biophys. J.* 70, 1294–1302.
- O'Carroll, S.J., Alkadi, M., Nicholson, L.F., Green, C.R., 2008. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. *Cell Commun. Adhes.* 15, 27–42.
- O'Carroll, S.J., Gorrie, C.A., Velamoor, S., Green, C.R., Nicholson, L.F., 2013. Connexin43 mimetic peptide is neuroprotective and improves function following spinal cord injury. *Neurosci. Res.* 75, 256–267.
- O'Quinn, M.P., Palatinus, J.A., Harris, B.S., Hewett, K.W., Gourdie, R.G., 2011. A peptide mimetic of the connexin43 carboxyl terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. *Circ. Res.* 108, 704–715.
- Orellana, J.A., Froger, N., Ezan, P., Jiang, J.X., Bennett, M.V., Naus, C.C., Giaume, C., Saez, J.C., 2011a. ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels. *J. Neurochem.* 118, 826–840.
- Orellana, J.A., Shoji, K.F., Abudara, V., Ezan, P., Amigou, E., Saez, P.J., Jiang, J.X., Naus, C.C., Saez, J.C., Giaume, C., 2011b. Amyloid beta-induced death in neurons involves glial and neuronal hemichannels. *J. Neurosci.* 31, 4962–4977.
- Palatinus, J.A., O'Quinn, M.P., Barker, R.J., Harris, B.S., Jourdan, J., Gourdie, R.G., 2011a. ZO-1 determines adherens and gap junction localization at intercalated disks. *Am. J. Physiol. Heart Circ. Physiol.* 300, H583–H594.
- Palatinus, J.A., Rhett, J.M., Gourdie, R.G., 2011b. Enhanced PKCepsilon mediated phosphorylation of connexin43 at serine 368 by a carboxyl-terminal mimetic peptide is dependent on injury. *Channels (Austin)* 5, 236–240.
- Palatinus, J.A., Rhett, J.M., Gourdie, R.G., 2012. The connexin43 carboxyl terminus and cardiac gap junction organization. *Biochim. Biophys. Acta* 1818, 1831–1843.
- Paul, D.L., Ebihara, L., Takemoto, L.J., Swenson, K.I., Goodenough, D.A., 1991. Connexin46, a novel lens gap junction protein, induces voltage-gated currents in nonjunctional plasma membrane of *Xenopus* oocytes. *J. Cell Biol.* 115, 1077–1089.
- Ponsaerts, R., D'hondt, C., Bultynck, G., Srinivas, S.P., Vereecke, J., Himpens, B., 2008. The myosin II ATPase inhibitor blebbistatin prevents thrombin-induced inhibition of intercellular calcium wave propagation in corneal endothelial cells. *Invest. Ophthalmol. Vis. Sci.* 49, 4816–4827.

- Ponsaerts, R., D'Hondt, C., Hertens, F., Parys, J.B., Leybaert, L., Vereecke, J., Himpens, B., Bultynck, G., 2012a. RhoA GTPase switch controls Cx43-hemichannel activity through the contractile system. *PLoS One* 7, e42074.
- Ponsaerts, R., De Vuyst, E., Retamal, M., D'hondt, C., Vermeire, D., Wang, N., De Smedt, H., Zimmermann, P., Himpens, B., Vereecke, J., Leybaert, L., Bultynck, G., 2010. Intramolecular loop/tail interactions are essential for connexin 43-hemichannel activity. *FASEB J.* 24, 4378–4395.
- Ponsaerts, R., Wang, N., Himpens, B., Leybaert, L., Bultynck, G., 2012b. The contractile system as a negative regulator of the connexin 43 hemichannel. *Biol. Cell* 104, 367–377.
- Postma, F.R., Hengeveld, T., Alblas, J., Giepmans, B.N., Zondag, G.C., Jalink, K., Moolenaar, W.H., 1998. Acute loss of cell-cell communication caused by G protein-coupled receptors: a critical role for c-Src. *J. Cell Biol.* 140, 1199–1209.
- Retamal, M.A., Cortes, C.J., Reuss, L., Bennett, M.V., Saez, J.C., 2006. S-nitrosylation and permeation through connexin 43 hemichannels in astrocytes: induction by oxidant stress and reversal by reducing agents. *Proc. Natl. Acad. Sci. U.S.A.* 103, 4475–4480.
- Retamal, M.A., Froger, N., Palacios-Prado, N., Ezan, P., Saez, P.J., Saez, J.C., Giaume, C., 2007a. Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. *J. Neurosci.* 27, 13781–13792.
- Retamal, M.A., Schalper, K.A., Shoji, K.F., Bennett, M.V., Saez, J.C., 2007b. Opening of connexin 43 hemichannels is increased by lowering intracellular redox potential. *Proc. Natl. Acad. Sci. U.S.A.* 104, 8322–8327.
- Retamal, M.A., Schalper, K.A., Shoji, K.F., Orellana, J.A., Bennett, M.V., Saez, J.C., 2007c. Possible involvement of different connexin43 domains in plasma membrane permeabilization induced by ischemia-reperfusion. *J. Membr. Biol.* 218, 49–63.
- Rhett, J.M., Ghatnekar, G.S., Palatinus, J.A., O'Quinn, M., Yost, M.J., Gourdie, R.G., 2008. Novel therapies for scar reduction and regenerative healing of skin wounds. *Trends Biotechnol.* 26, 173–180.
- Rhett, J.M., Gourdie, R.G., 2012. The perinexus: a new feature of Cx43 gap junction organization. *Heart Rhythm* 9, 619–623.
- Rhett, J.M., Jourdan, J., Gourdie, R.G., 2011. Connexin 43 connexon to gap junction transition is regulated by zonula occludens-1. *Mol. Biol. Cell* 22, 1516–1528.
- Saez, J.C., Berthoud, V.M., Branes, M.C., Martinez, A.D., Beyer, E.C., 2003. Plasma membrane channels formed by connexins: their regulation and functions. *Physiol. Rev.* 83, 1359–1400.
- Santello, M., Cali, C., Bezzi, P., 2012. Gliotransmission and the tripartite synapse. *Adv. Exp. Med. Biol.* 970, 307–331.
- Scemes, E., 2012. Nature of plasmalemmal functional “hemichannels”. *Biochim. Biophys. Acta* 1818, 1880–1883.
- Scemes, E., Spray, D.C., Meda, P., 2009. Connexins, pannexins, innexins: novel roles of “hemi-channels”. *Pflügers Arch.* 457, 1207–1226.
- Scemes, E., Suardicani, S.O., Dahl, G., Spray, D.C., 2007. Connexin and pannexin mediated cell-cell communication. *Neuron Glia Biol.* 3, 199–208.
- Schalper, K.A., Palacios-Prado, N., Retamal, M.A., Shoji, K.F., Martinez, A.D., Saez, J.C., 2008. Connexin hemichannel composition determines the FGF-1-induced membrane permeability and free $[Ca^{2+}]_i$ responses. *Mol. Biol. Cell* 19, 3501–3513.
- Schalper, K.A., Riquelme, M.A., Branes, M.C., Martinez, A.D., Vega, J.L., Berthoud, V.M., Bennett, M.V., Saez, J.C., 2012. Modulation of gap junction channels and hemichannels by growth factors. *Mol. Biosyst.* 8, 685–698.
- Scolari, M.J., Acosta, G.B., 2007. D-Serine: a new word in the glutamatergic neuroglial language. *Amino Acids* 33, 563–574.
- Seki, A., Coombs, W., Taffet, S.M., Delmar, M., 2004a. Loss of electrical communication, but not plaque formation, after mutations in the cytoplasmic loop of connexin43. *Heart Rhythm* 1, 227–233.
- Seki, A., Duffy, H.S., Coombs, W., Spray, D.C., Taffet, S.M., Delmar, M., 2004b. Modifications in the biophysical properties of connexin43 channels by a peptide of the cytoplasmic loop region. *Circ. Res.* 95, e22–e28.
- Severs, N.J., 1994. Gap junction alterations in the failing heart. *Eur. Heart J.* 15 (Suppl. D), 53–57.
- Shibayama, J., Gutierrez, C., Gonzalez, D., Kieken, F., Seki, A., Carrion, J.R., Sorgen, P.L., Taffet, S.M., Barrio, L.C., Delmar, M., 2006. Effect of charge substitutions at residue his-142 on voltage gating of connexin43 channels. *Biophys. J.* 91, 4054–4063.
- Shintani-Ishida, K., Uemura, K., Yoshida, K., 2007. Hemichannels in cardiomyocytes open transiently during ischemia and contribute to reperfusion injury following brief ischemia. *Am. J. Physiol. Heart Circ. Physiol.* 293, H1714–H1720.
- Shiroshita-Takeshita, A., Sakabe, M., Haugan, K., Hennan, J.K., Nattel, S., 2007. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. *Circulation* 115, 310–318.
- Siebert, A.P., Ma, Z., Grevet, J.D., Demuro, A., Parker, I., Foskett, J.K., 2013. Structural and functional similarities of calcium homeostasis modulator 1 (CALHM1) ion channel with connexins, pannexins, and innexins. *J. Biol. Chem.* 288, 6140–6153.
- Simi, A., Tsakiri, N., Wang, P., Rothwell, N.J., 2007. Interleukin-1 and inflammatory neurodegeneration. *Biochem. Soc. Trans.* 35, 1122–1126.
- Solan, J.L., Lampe, P.D., 2009. Connexin43 phosphorylation: structural changes and biological effects. *Biochem. J.* 419, 261–272.
- Sorgen, P.L., Duffy, H.S., Sahoo, P., Coombs, W., Delmar, M., Spray, D.C., 2004a. Structural changes in the carboxyl terminus of the gap junction protein connexin43 indicates signaling between binding domains for c-Src and zonula occludens-1. *J. Biol. Chem.* 279, 54695–54701.
- Sorgen, P.L., Duffy, H.S., Spray, D.C., Delmar, M., 2004b. pH-dependent dimerization of the carboxyl terminal domain of Cx43. *Biophys. J.* 87, 574–581.
- Sosinsky, G.E., Boassa, D., Dermietzel, R., Duffy, H.S., Laird, D.W., MacVicar, B., Naus, C.C., Penuela, S., Scemes, E., Spray, D.C., Thompson, R.J., Zhao, H.B., Dahl, G., 2011. Pannexin channels are not gap junction hemichannels. *Channels (Austin)* 5, 193–197.
- Spray, D.C., Harris, A.L., Bennett, M.V., 1981. Gap junctional conductance is a simple and sensitive function of intracellular pH. *Science* 211, 712–715.
- Srisakuldee, W., Jeyaraman, M.M., Nickel, B.E., Tanguy, S., Jiang, Z.S., Kardami, E., 2009. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. *Cardiovasc. Res.* 83, 672–681.
- Stehberg, J., Moraga-Amaro, R., Salazar, C., Becerra, A., Echeverria, C., Orellana, J.A., Bultynck, G., Ponsaerts, R., Leybaert, L., Simon, F., Saez, J.C., Retamal, M.A., 2012. Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala. *FASEB J.* 26, 3649–3657.
- Stergioupolous, K., Alvarado, J.L., Mastroianni, M., Ek-Vitorin, J.F., Taffet, S.M., Delmar, M., 1999. Hetero-domain interactions as a mechanism for the regulation of connexin channels. *Circ. Res.* 84, 1144–1155.
- Taruno, A., Vingtdoux, V., Ohmoto, M., Ma, Z., Dvoryanchikov, G., Li, A., Adrien, L., Zhao, H., Leung, S., Abernethy, M., Koppel, J., Davies, P., Civan, M.M., Chaudhuri, N., Matsumoto, I., Hellekant, G., Tordoff, M.G., Marambaud, P., Foskett, J.K., 2013. CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. *Nature* 495, 223–226.
- Torres, A., Wang, F., Xu, Q., Fujita, T., Dobrowolski, R., Willecke, K., Takano, T., Nedergaard, M., 2012. Extracellular $Ca^{2+}(+)$ acts as a mediator of communication from neurons to glia. *Sci. Signal.* 5, ra8.
- Toyofuku, T., Akamatsu, Y., Zhang, H., Kuzuya, T., Tada, M., Hori, M., 2001. c-Src regulates the interaction between connexin-43 and ZO-1 in cardiac myocytes. *J. Biol. Chem.* 276, 1780–1788.
- Toyofuku, T., Yabuki, M., Otsu, K., Kuzuya, T., Hori, M., Tada, M., 1998. Direct association of the gap junction protein connexin-43 with ZO-1 in cardiac myocytes. *J. Biol. Chem.* 273, 12725–12731.
- Vanden Abeele, F., Bidaux, G., Gordienko, D., Beck, B., Panchin, Y.V., Baranova, A.V., Ivanov, D.V., Skryma, R., Prevratskaya, N., 2006. Functional implications of calcium permeability of the channel formed by pannexin 1. *J. Cell Biol.* 174, 535–546.
- Verkhatsky, A., Parpura, V., 2010. Recent advances in (patho)physiology of astroglia. *Acta Pharmacol. Sin.* 31, 1044–1054.
- Verma, V., Larsen, B.D., Coombs, W., Lin, X., Sarrou, E., Taffet, S.M., Delmar, M., 2010. Design and characterization of the first peptidomimetic molecule that prevents acidification-induced closure of cardiac gap junctions. *Heart Rhythm* 7, 1491–1498.
- Verma, V., Larsen, B.D., Coombs, W., Lin, X., Spagnol, G., Sorgen, P.L., Taffet, S.M., Delmar, M., 2009. Novel pharmacophores of connexin43 based on the “RXP” series of Cx43-binding peptides. *Circ. Res.* 105, 176–184.
- Verselis, V.K., Bukauskas, F.F., 2002. Connexin-GFPs shed light on regulation of cell-cell communication by gap junctions. *Curr. Drug Targets* 3, 483–499.
- Volterra, A., Meldolesi, J., 2005. Astrocytes, from brain glue to communication elements: the revolution continues. *Nat. Rev. Neurosci.* 6, 626–640.
- Wang, N., De Bock, M., Antoons, G., Gadicherla, A.K., Bol, M., Decroock, E., Evans, W.H., Sipido, K.R., Bukauskas, F.F., Leybaert, L., 2012. Connexin mimetic peptides inhibit Cx43 hemichannel opening triggered by voltage and intracellular Ca^{2+} elevation. *Basic Res. Cardiol.* 107, 304.
- Wang, N., De Bock, M., Decroock, E., Bol, M., Gadicherla, A., Vinken, M., Rogiers, V., Bukauskas, F.F., Bultynck, G., Leybaert, L., 2013a. Paracrine signaling through plasma membrane hemichannels. *Biochim. Biophys. Acta* 1828, 35–50.
- Wang, N., De Vuyst, E., Ponsaerts, R., Boengler, K., Palacios-Prado, N., Wauman, J., Lai, C.P., De Bock, M., Decroock, E., Bol, M., Vinken, M., Rogiers, V., Tavernier, J., Evans, W.H., Naus, C.C., Bukauskas, F.F., Sipido, K.R., Heusch, G., Schulz, R., Bultynck, G., Leybaert, L., 2013b. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. *Basic Res. Cardiol.* 108, 309.
- Wang, R., Zhang, C., Ruan, Y., Liu, N., Wang, L., 2007. Changes in phosphorylation of connexin43 in rats during acute myocardial hypoxia and effects of antiarrhythmic peptide on the phosphorylation. *J. Huazhong Univ. Sci. Technol. Med. Sci.* 27, 241–244.
- Weng, S., Lauen, M., Schaefer, T., Polontchouk, L., Grover, R., Dhein, S., 2002. Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. *FASEB J.* 16, 1114–1116.
- Wiegerinck, R.F., de Bakker, J.M., Opthof, T., de Jonge, N., Kirkels, H., Wilms-Schopman, F.J., Coronel, R., 2009. The effect of enhanced gap junctional conductance on ventricular conduction in explanted hearts from patients with heart failure. *Basic Res. Cardiol.* 104, 321–332.
- Wit, A.L., Duffy, H.S., 2008. Drug development for treatment of cardiac arrhythmias: targeting the gap junctions. *Am. J. Physiol. Heart Circ. Physiol.* 294, H16–H18.